Hypera S.A.

Quarterly information report

June 30, 2026

Content

Hypera Pharma reports 8.5% Net Revenue growth, with Net Income from Continuing Operations increasing 15.0% and Operating Cash Flow growing 85.0%

São Paulo, August 06, 2026 – Hypera S.A. (“Hypera Pharma” or “Company”; B3: HYPE3; Bloomberg: HYPE3 BZ; ISIN: BRHYPEACNOR0; Reuters: HYPE3.SA; ADR: HYPMY) announces its financial results for the 2nd quarter of 2026. Financial data disclosed here are taken from the consolidated financial statements of Hypera S.A., prepared in accordance with the Brazilian Accounting Pronouncement Committee (CPC) and the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB).

2Q26 Highlights

- 7.6%[1] sell-out growth in pharma retail, 1.4 p.p. above the growth in the categories in which the Company operates
- Net Revenue of R$2,336.7 million, 8.5% higher than in 2Q25
- Gross Margin of 61.8% in the quarter, 1.7 percentage point above 2Q25
- Net Income from Continuing Operations of R$490.0 million, 15.0% higher than in 2Q25
- Reduction in working capital investments to 28% of Net Revenue[2], compared to 32% in 2Q25
- Cash Flow from Operations of R$819.2 million, or 108.5% of EBITDA from Continuing Operations
- Net Debt reduced to R$5,903.5 million, down R$397.6 million versus the end of 1Q26
- Interest on Equity approval of R$185.2 million (R$0.26/share)

Table 1

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
Net Revenue	2,153.9	*100.0%*	2,336.7	*100.0%*	*8.5%*	3,234.8	*100.0%*	4,354.5	*100.0%*	*34.6%*
Gross Profit	1,295.1	*60.1%*	1,443.7	*61.8%*	*11.5%*	1,805.3	*55.8%*	2,654.3	*61.0%*	*47.0%*
EBITDA from Continuing Operations	725.4	*33.7%*	754.9	*32.3%*	*4.1%*	576.9	*17.8%*	1,341.4	*30.8%*	*132.5%*
Net Income from Continuing Operations	426.1	*19.8%*	490.0	*21.0%*	*15.0%*	287.3	*8.9%*	835.7	*19.2%*	*190.9%*
Cash Flow from Operations	442.8	*20.6%*	819.2	*35.1%*	*85.0%*	1,012.7	*31.3%*	1,340.1	*30.8%*	*32.3%*
Free Cash Flow	204.6	*9.5%*	637.8	*27.3%*	*211.6%*	552.9	*17.1%*	1,005.5	*23.1%*	*81.9%*

EARNINGS CONFERENCE CALL – PORTUGUESE: August 7th, 2026, at 11am (Brasília) / 10am (New York)
Webcast: click here / **Phone:** +55 (11) 4700-9668 **ID**: 883 4464 1800 **Passcode:** 648414
Replay: ri.hypera.com.br

EARNINGS CONFERENCE CALL – ENGLISH: (Simultaneous translation): August 7th, 2026, at 11am (Brasília) / 10am (New York)
Webcast: click here / **Phone:** +1 (720) 707-2699 **ID**: 883 4464 1800 **Passcode:** 648414
Replay: ri.hypera.com.br/en

IR contacts
+55 (11) 3627-4206
ri@hypera.com.br

Note: (1) Sell-out PPP (Pharmacy Purchase Price); (2) Considers the annualized Net Revenue for the quarter

Operating Scenario

Hypera Pharma reported Net Revenue of R$2,336.7 million, 8.5% higher than in 2Q25. This growth was driven by a 7.6%[1] increase in sell-out in the pharmaceutical retail market compared to the same period last year, with the performance in Gastroenterology, Cardiology, and Skincare standing out.

Sell-out performance was once again supported by new product launches, which added 2.2 percentage points to sell-out growth in 2Q26, contributing to the Company's sell-out growth being 1.4 percentage point above market growth in the categories in which it operates. In 1H26, sell-out growth reached 8.8%, or 1.6 percentage point above market growth in the categories in which the Company operates.

Gross Profit increased 11.5% and totaled R$1,443.7 million, with a 61.8% margin, compared to 60.1% in 2Q25 and 60.0% in 1Q26, contributing to EBITDA from Continuing Operations reaching R$754.9 million, with a 32.3% margin. Net Income from Continuing Operations totaled R$490.0 million and expanded 15.0% in the period, mainly benefiting from lower financial expenses due to the R$1.5 billion capital increase carried out at the end of 1Q26, which contributed to the reduction in net debt in the last quarter.

In addition to the expansion in Net Revenue, EBITDA from Continuing Operations, and Net Income from Continuing Operations, the Company made significant progress in its strategy to reduce inventories of raw materials and finished products, supported by the recent improvement in its key logistics efficiency indicators resulting from the optimization of the product mix at points of sale and greater agility in client order deliveries, following the new sell-out monitoring methodology implemented last year.

The Company ended the quarter with R$1,927,0 million in Inventories, compared to R$2,066.0 million in 1Q26 and R$2,108.3 million in 2Q25. This reduction in Inventories contributed to reducing working capital investments as a percentage of annualized Net Revenue in the quarter to 28%, compared to 32% in 2Q25 and 30% in 4Q25, allowing the Company to increase its operating cash flow generation to R$819.2 million in 2Q26, corresponding to 108.5% of EBITDA from Continuing Operations.

The combination of operating results growth and lower working capital investments in 2Q26 also contributed to the reduction in Net Debt, which ended the quarter at R$5,903.5 million, compared to R$6,301.1 million at the end of 1Q26, or 2.1x the LTM EBITDA from Continuing Operations.

Hypera Pharma strengthened its portfolio expansion strategy through the announcement of a strategic partnership with Astellas for the commercialization of treatments for vasomotor symptoms associated with menopause, as well as the approval of Semavy at the beginning of 3Q26, which marked the beginning of the Company's operations in the Brazilian GLP-1 analog market, primarily used for the treatment of type 2 diabetes and obesity.

The strategic partnership with Astellas, a Japanese-origin global pharmaceutical company, will enable the launch of a new brand based on fezolinetant, a molecule protected by patent until 2034, for the innovative non-hormonal treatment of vasomotor symptoms associated with menopause. According to estimates, these symptoms may affect up to 80%[3] of the 30 million Brazilian women currently living through peri or post menopause. Through this partnership, the Company will accelerate the population access to one of the most relevant innovations in women's health in recent decades, expanding its portfolio in this category following the launch of its new brand, expected in the first half of 2027.

Semavy, approved by ANVISA – Brazil's Health Regulatory Agency – at the beginning of 3Q26 following a rigorous assessment of quality, safety, and efficacy evidence, reinforces the Company's growth strategy in the Brazilian pharmaceutical market through the launch of innovative therapies in relevant markets with attractive growth potential.

The GLP-1 analog market has already exceeded R$13.1 billion[1] in sales over the last twelve months in Brazil, and Hypera Pharma's participation in this market through Mantecorp, its umbrella brand for Prescription Products widely recommended by the Brazilian medical community, will significantly contribute to expanding access for the Brazilian population to semaglutide-based treatments.

Hypera Pharma once again demonstrated this quarter its ability to combine sustainable sell-out growth with robust operating cash flow generation, key attributes to maintain its commitment to shareholder remuneration, evidenced by the approval of Interest on Equity of R$185.2 million (R$0.26/share), while continuing to advance innovation and portfolio expansion through both the launch of innovative therapies in the Brazilian pharmaceutical market and line extensions of its leading brands.

Notes: *(1) Sell-out PPP (Pharmacy Purchase Price), as reported by IQVIA, considers the average purchase price paid by pharmacies and pharmacy chains; (2) considers launches from the last 12 months; (3) according to estimates from IBGE and Climateric.*

Earnings Discussion

Income Statement

Table 2

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
Net Revenue	**2,153.9**	***100.0%***	**2,336.7**	***100.0%***	***8.5%***	**3,234.8**	***100.0%***	**4,354.5**	***100.0%***	***34.6%***
Gross Profit	**1,295.1**	***60.1%***	**1,443.7**	***61.8%***	***11.5%***	**1,805.3**	***55.8%***	**2,654.3**	***61.0%***	***47.0%***
Marketing Expenses	(361.4)	*-16.8%*	(410.9)	*-17.6%*	*13.7%*	(728.6)	*-22.5%*	(746.7)	*-17.1%*	*2.5%*
Selling Expenses	(229.5)	*-10.7%*	(272.3)	*-11.7%*	*18.7%*	(491.7)	*-15.2%*	(541.7)	*-12.4%*	*10.2%*
General and Administrative Expenses	(72.9)	*-3.4%*	(97.4)	*-4.2%*	*33.6%*	(159.1)	*-4.9%*	(195.6)	*-4.5%*	*22.9%*
Other Operating Revenues (Expenses)	12.1	*0.6%*	10.5	*0.4%*	*-13.4%*	(7.5)	*-0.2%*	9.1	*0.2%*	-
Equity in Subsidiaries	3.3	*0.2%*	(4.5)	*-0.2%*	-	2.1	*0.1%*	(7.8)	*-0.2%*	-
EBIT from Continuing Operations	**646.7**	***30.0%***	**669.0**	***28.6%***	***3.5%***	**420.6**	***13.0%***	**1,171.6**	***26.9%***	***178.5%***
Net Financial Expenses	(212.7)	*-9.9%*	(176.7)	*-7.6%*	*-16.9%*	(407.9)	*-12.6%*	(403.1)	*-9.3%*	*-1.2%*
Income Tax and CSLL	(7.9)	*-0.4%*	(2.3)	*-0.1%*	*-71.2%*	274.5	*8.5%*	67.3	*1.5%*	*-75.5%*
Net Income from Continuing Operations	426.1	*19.8%*	490.0	*21.0%*	*15.0%*	287.3	*8.9%*	835.7	*19.2%*	*190.9%*
Net Income from Discontinued Operations	(0.7)	*0.0%*	0.2	*0.0%*	-	(3.0)	*-0.1%*	1.4	*0.0%*	-
Net Income	425.4	*19.8%*	490.2	*21.0%*	*15.2%*	284.3	*8.8%*	837.1	*19.2%*	*194.5%*
EBITDA from Continuing Operations	**725.4**	***33.7%***	**754.9**	***32.3%***	***4.1%***	**576.9**	***17.8%***	**1,341.4**	***30.8%***	***132.5%***

Net Revenue

Graph 1



Graph 2



Graph 3



Graph 4



Table 3

(R$ million)	2Q25	2Q26	Δ %	1H25	1H26	Δ %
Gross Revenue, net of Returns and Unconditional Discounts	**2,538.4**	**2,768.3**	***9.1%***	**3,934.4**	**5,165.6**	***31.3%***
Promotional Discounts	(206.4)	(230.2)	*11.5%*	(413.5)	(433.6)	*4.9%*
Taxes	(178.0)	(201.4)	*13.1%*	(286.0)	(377.5)	*32.0%*
Net Revenue	**2,153.9**	**2,336.7**	***8.5%***	**3,234.8**	**4,354.5**	***34.6%***

Net Revenue totaled R$2,336.7 million in the quarter, 8.5% higher than in 2Q25. The growth in Net Revenue was mainly driven by the recent increase in sell-out in the pharmaceutical retail market.

Gross Profit

Graph 5



Graph 6



Graph 7



Graph 8



Table 4

(R$ million)	2Q25	*% NR*	2Q26	*% NR*	*Δ %*	*Δ p.p.*	1H25	*% NR*	1H26	*% NR*	*Δ %*	*Δ p.p.*
Gross Profit	1,295.1	*60.1%*	1,443.7	*61.8%*	*11.5%*	*1.7 p.p.*	1,805.3	*55.8%*	2,654.3	*61.0%*	*47.0%*	*5.2 p.p.*

Gross Profit increased 11.5% and totaled R$1,443.7 million, with a 61.8% margin, 1.7 percentage point above the level recorded in 2Q25. The expansion in Gross Margin during the period was mainly driven by price increases across the Company's product portfolio at a level above the increase in costs.

Marketing Expenses

Table 5

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
Marketing Expenses	(361.4)	-16.8%	(410.9)	-17.6%	13.7%	(728.6)	-22.5%	(746.7)	-17.1%	2.5%
Advertisement and Consumer Promotion	(121.2)	-5.6%	(125.7)	-5.4%	3.6%	(262.8)	-8.1%	(230.0)	-5.3%	-12.5%
Trade Deals	(57.5)	-2.7%	(77.6)	-3.3%	35.1%	(121.3)	-3.7%	(138.8)	-3.2%	14.4%
Medical Visits, Promotions and Others	(182.7)	-8.5%	(207.6)	-8.9%	13.6%	(344.6)	-10.7%	(377.9)	-8.7%	9.7%

Marketing Expenses increased 13.7% in 2Q26 compared to 2Q25, totaling R$410.9 million. The increase in Marketing Expenses above the sell-out growth was mainly driven by: (i) the expansion of point-of-sale initiatives to increase the visibility of the Company's leading brands; and (ii) the expansion of medical representatives to support recent and upcoming Prescription Products launches, increasing promotional coverage and strengthening demand generation among the medical community.

In 1H26, Marketing Expenses increased 2.5%, below the sell-out growth in the same period, mainly due to the reduction in Advertising and Consumer Promotion expenses during the semester, following the strategic rescheduling of the 2026 campaign calendar in Consumer Health, aimed at greater alignment with the new product launches schedule and the year's key events.

Selling Expenses

Table 6

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
Selling Expenses	(229.5)	-10.7%	(272.3)	-11.7%	18.7%	(491.7)	-15.2%	(541.7)	-12.4%	10.2%
Commercial Expenses	(140.7)	-6.5%	(168.8)	-7.2%	20.0%	(303.7)	-9.4%	(331.9)	-7.6%	9.3%
Freight and Logistics Expenses	(49.3)	-2.3%	(69.6)	-3.0%	41.2%	(102.2)	-3.2%	(138.3)	-3.2%	35.2%
Research & Development	(39.5)	-1.8%	(33.9)	-1.4%	-14.2%	(85.7)	-2.7%	(71.5)	-1.6%	-16.7%

Selling Expenses totaled R$272.3 million in 2Q26, in line with the level recorded in 1Q26, and represented 11.7% of Net Revenue in the quarter.

Compared to 2Q25, Selling Expenses increased 18.7%, mainly driven by: (i) the increase in Commercial Expenses, primarily as a result of the 10.5% reduction in these expenses in 2Q25 compared to 2Q24; and (ii) the increase in Freight and Logistics Expenses, related to the Company's operational strategy of increasing delivery frequency, aimed at optimizing service levels and client supply.

The 14.2% reduction in Research and Development Expenses was mainly due to the R$12.0 million benefit from the Lei do Bem tax incentive booked in the quarter. Excluding the impact of this benefit, which was not booked in 2Q25, Research and Development Expenses in 2Q26 increased 16.2% compared to the same period last year.

General and Administrative Expenses & Other Operating Revenues / Expenses, Net

Table 7

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
General & Administrative Expenses	(72.9)	-3.4%	(97.4)	-4.2%	33.6%	(159.1)	-4.9%	(195.6)	-4.5%	22.9%
Other Operating Revenues (Expenses)	12.1	0.6%	10.5	0.4%	-13.4%	(7.5)	-0.2%	9.1	0.2%	-

General and Administrative Expenses totaled R$97.4 million in 2Q26, in line with the level recorded in 1Q26. The increase in General and Administrative Expenses compared to 2Q25 mainly reflects the lower level of expenses with administrative teams and advisory and consulting services recorded in that quarter, as well as the higher level of technology investments in 2Q26.

EBITDA from Continuing Operations

Graph 9



Graph 10



Graph 11



Graph 12



Table 8 – EBITDA from Continuing Operations

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
EBITDA from Continuing Operations	725.4	*33.7%*	754.9	*32.3%*	*4.1%*	576.9	*17.8%*	1,341.4	*30.8%*	*132.5%*
EBITDA from Continuing Operations (excl. Others)	713.3	*33.1%*	744.5	*31.9%*	*4.4%*	584.3	*18.1%*	1,332.3	*30.6%*	*128.0%*

EBITDA from Continuing Operations totaled R$754.9 million, with a 32.3% margin. The growth in EBITDA from Continuing Operations was below the growth in Net Revenue mainly due to the increase in Marketing, Selling, and General and Administrative Expenses as a percentage of Net Revenue in the period.

Net Financial Expenses

Table 9

(R$ million)	2Q25	% NR	2Q26	% NR	Δ R$	1H25	% NR	1H26	% NR	Δ R$
Financial Result	(212.7)	-9.9%	(176.7)	-7.6%	35.9	(407.9)	-12.6%	(403.1)	-9.3%	4.7
Net Interest Expenses	(204.0)	-9.5%	(146.6)	-6.3%	57.4	(392.4)	-12.1%	(364.2)	-8.4%	28.1
Cost of Hedge and FX Gains (Losses)	10.9	0.5%	2.6	0.1%	(8.2)	27.5	0.9%	18.0	0.4%	(9.5)
Other	(19.5)	-0.9%	(32.8)	-1.4%	(13.3)	(43.1)	-1.3%	(56.9)	-1.3%	(13.9)

Financial Result was negative by R$176.7 million in 2Q26, R$35.9 million lower than in 2Q25. This variation was mainly driven by the 28.1% reduction in Net Interest Expenses, primarily resulting from the reduction in Net Debt following the R$1.5 billion private capital increase approved by the Board of Directors at the end of 1Q26.

Net Income

Table 10

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
EBIT from Continuing Operations	646.7	30.0%	669.0	28.6%	3.5%	420.6	13.0%	1,171.6	26.9%	178.5%
(-) Financial Result	(212.7)	-9.9%	(176.7)	-7.6%	-16.9%	(407.9)	-12.6%	(403.1)	-9.3%	-1.2%
(-) Income Tax and Social Contribution	(7.9)	-0.4%	(2.3)	-0.1%	-71.2%	274.5	8.5%	67.3	1.5%	-75.5%
Net Income from Continuing Operations	**426.1**	**19.8%**	**490.0**	**21.0%**	**15.0%**	**287.3**	**8.9%**	**835.7**	**19.2%**	**190.9%**
(+) Net Income from Discontinued Operations	(0.7)	0.0%	0.2	0.0%	-	(3.0)	-0.1%	1.4	0.0%	-
Net Income	**425.4**	**19.8%**	**490.2**	**21.0%**	**15.2%**	**284.3**	**8.8%**	**837.1**	**19.2%**	**194.5%**
EPS	**0.68**	**-**	**0.70**	**-**	**4.3%**	**0.45**	**-**	**1.25**	**-**	**176.1%**
EPS from Continuing Operations	**0.67**	**-**	**0.70**	**-**	**4.7%**	**0.45**	**-**	**1.25**	**-**	**175.1%**

Net Income from Continuing Operations increased 15.0% and totaled R$490.0 million. The growth in Net Income from Continuing Operations above the growth in EBIT from Continuing Operations was mainly driven by the 16.9% reduction in Financial Result.

Cash Flow (Continuing and Discontinued Operations)

Graph 13



Graph 14



Graph 15



Graph 16



Table 11

(R$ million)	2Q25	2Q26	1H25	1H26
Cash Flow from Operations	442.8	819.2	1,012.7	1,340.1
Purchase of Property, Plant and Equipment	(158.2)	(75.7)	(305.5)	(154.6)
Purchase of Intangible Assets	(67.3)	(56.1)	(129.6)	(115.6)
Others	(12.7)	(49.7)	(24.7)	(64.4)
(=) Free Cash Flow	**204.6**	**637.8**	**552.9**	**1,005.5**

Cash Flow from Operations totaled R$819.2 million in 2Q26, representing 108.5% of EBITDA from Continuing Operations. In 1H26, Cash Flow from Operations reached the same level as EBITDA from Continuing Operations, reflecting the Company's disciplined working capital management and its strong ability to convert operating results into cash.

In 2Q26, Cash Flow from Operations was benefited by the reduction in Inventories, which ended the quarter at R$1,927.0 million, compared to R$2,066.0 million in 1Q26. This reduction is also part of the strategy to gradually reduce internal inventories of raw materials and finished products, mainly supported by the recent improvement in the Company's key logistics efficiency indicators.

The increase in Cash Flow from Operations, combined with the lower level of Purchases of Property, Plant and Equipment and Intangible Assets during the period, contributed to the Company achieving Free Cash Flow of R$637.8 million in the quarter.

Net Debt

Table 12

(R$ million)	03/31/2026	06/30/2026
Loans and Financing	(8,543.7)	(7,462.8)
Notes Payable	(68.3)	(19.2)
Gross Debt	**(8,612.0)**	**(7,482.0)**
Cash and Cash Equivalents	2,310.9	1,578.5
Net Cash / (Debt)	**(6,301.1)**	**(5,903.5)**

The Company ended 2Q26 with Net Debt of R$5,903.5 million, compared to R$6,301.1 million at the end of 1Q26, representing 2.1x the LTM EBITDA from Continuing Operations. The R$397.6 million reduction in Net Debt was mainly driven by the free cash flow generation in the quarter.

Other Information

Cash Conversion Cycle – Continuing Operations

Table 13

(Days)	2Q25	3Q25	4Q25	1Q26	2Q26
Receivables [(1)]	60	58	61	66	60
Inventories [(2)]	221	221	218	230	194
Payables [(2) (3)]	(94)	(110)	(112)	(108)	(101)
Cash Conversion Cycle	**187**	**169**	**167**	**188**	**153**

(R$ million)	2Q25	3Q25	4Q25	1Q26	2Q26
Receivables	1,588	1,593	1,688	1,648	1,705
Inventories	2,108	2,129	2,079	2,066	1,927
Payables [(3)]	(897)	(1,056)	(1,065)	(970)	(1,006)
Working Capital	**2,799**	**2,667**	**2,702**	**2,744**	**2,626**
% of Annualized Net Revenue [(4)]	***32%***	***30%***	***30%***	***34%***	***28%***

(1) Calculated based on Continuing Operations Gross Revenue, Net of Discounts
(2) Calculated based on Continuing Operations COGS
(3) Includes Suppliers' Assignment of Receivables
(4) Annualized Net Revenue for the last 3 months

Tax Credits that offset Income Tax cash payment

i) **Federal Tax Credits:** R$346.8 million (see Note 13 to the Quarterly Financial Information)

ii) **Cash Effect of Tax Losses and Negative CSLL Bases:** R$5,666.9 million (see Note 21(a) to the Quarterly Financial Information)

iii) **Goodwill:** the Company has R$156.8 million in goodwill to be amortized for tax purposes through 2030, which will result in a reduction in cash outflows for Income Tax payments of R$53.3 million.

Reconciliation of Adjusted EBITDA, or EBITDA from Continuing Operations Calculation

Table 14

(R$ million)	2Q25	% NR	2Q26	% NR	Δ %	1H25	% NR	1H26	% NR	Δ %
Net Income	425.4	*19.8%*	490.2	*21.0%*	*15.2%*	284.3	*8.8%*	837.1	*19.2%*	*194.5%*
(+) Income Tax and CSLL	7.5	*0.4%*	2.4	*0.1%*	*-68.3%*	(276.1)	*-8.5%*	(66.6)	*-1.5%*	*-75.9%*
(+) Net Interest Expenses	212.7	*9.9%*	176.7	*7.6%*	*-16.9%*	407.9	*12.6%*	403.1	*9.3%*	*-1.2%*
(+) Depreciations / Amortizations	78.7	*3.7%*	85.9	*3.7%*	*9.1%*	156.3	*4.8%*	169.9	*3.9%*	*8.7%*
EBITDA	**724.4**	***33.6%***	**755.3**	***32.3%***	***4.3%***	**572.3**	***17.7%***	**1,343.5**	***30.9%***	***134.7%***
(-) EBITDA from Discontinued Operations	1.0	*0.0%*	(0.3)	*0.0%*	*-*	4.5	*0.1%*	(2.1)	*0.0%*	*-*
Adjusted EBITDA (EBITDA from Continuing Operations)	**725.4**	***33.7%***	**754.9**	***32.3%***	***4.1%***	**576.9**	***17.8%***	**1,341.4**	***30.8%***	***132.5%***

EBITDA is a non-accounting measure prepared by the Company and it is calculated based on net income, added by income taxes, financial expenses net of financial income, depreciation and amortization. The Adjusted EBITDA, or EBITDA from Continuing Operations, represents EBITDA, excluding the effects related to discontinued operations that affected the Company's EBITDA. The Company uses Adjusted EBITDA, or EBITDA from Continuing Operations, as a non-accounting measure, to present its performance in a way that better translates the operating cash generation potential of its business.

Disclaimer

This release contains forward-looking statements that are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its continued access to capital to fund its business plan. These forward-looking statements substantially depend on changing market conditions, government regulations, competitive pressures, the performance of the Brazilian economy and the industry, among other factors, as well as the risks shown in our filed disclosure documents, and are therefore subject to change without prior notice.

Additional unaudited information herein reflects management's interpretation of information taken from its financial information and their respective adjustments, which were prepared in accordance with market practices and for the sole purpose of a more detailed and specific analysis of our results. Therefore, this additional data must also be analyzed and interpreted independently by shareholders and market agents, who should carry out their own analysis and draw their own conclusions from the results reported herein. No data or interpretative analysis provided by our management should be treated as a guarantee of future performance or results and are merely illustrative of our directors' vision of our results.

Our management is not responsible for compliance or accuracy of the management financial data discussed in this report, which must be considered for informational purposes only, and should not override the analysis of our audited consolidated financial statements or our reviewed quarterly information for purposes of a decision to invest in our stock, or for any other purpose.

Consolidated Income Statement (R$ thousand)

Table 15

	2Q25	2Q26	1H25	1H26
Net Revenue	**2,153,937**	**2,336,699**	**3,234,843**	**4,354,477**
Cost of Goods Sold	(858,851)	(892,990)	(1,429,494)	(1,700,205)
Gross Profit	**1,295,086**	**1,443,709**	**1,805,349**	**2,654,272**
Selling and Marketing Expenses	(590,891)	(683,246)	(1,220,320)	(1,288,397)
General and Administrative Expenses	(72,944)	(97,440)	(159,100)	(195,564)
Other Operating Revenues (Expenses)	12,098	10,473	(7,459)	9,075
Equity in Subsidiaries	3,307	(4,488)	2,147	(7,833)
Operating Income Before Equity Income and Financial Result	**646,656**	**669,008**	**420,617**	**1,171,553**
Net Financial Expenses	(212,662)	(176,717)	(407,864)	(403,125)
Financial Expenses	(262,045)	(239,733)	(507,102)	(530,802)
Financial Income	49,383	63,016	99,238	127,677
Profit Before Income Tax and Social Contribution	**433,994**	**492,291**	**12,753**	**768,428**
Income Tax and Social Contribution	(7,898)	(2,276)	274,520	67,268
Net Income from Contining Operations	**426,096**	**490,015**	**287,273**	**835,696**
Net Income from Discontinued Operations	(682)	221	(3,001)	1,381
Income for the Period	**425,414**	**490,236**	**284,272**	**837,077**
Earnings per Share – R$	**0.68**	**0.70**	**0.45**	**1.25**

Consolidated Balance Sheet (R$ thousand)

Table 16

Assets	12/31/2025	06/30/2026
Current Assets	**6,048,363**	**5,941,916**
Cash and Cash Equivalents	1,645,541	1,578,512
Accounts Receivables	1,688,362	1,705,036
Inventories	2,079,176	1,927,036
Recoverable Taxes	387,963	541,252
Financial Derivatives	26,790	2,383
Other Assets	214,302	187,697
Dividends and IOC receivables	6,229	-
Non-Current Assets	**19,109,641**	**19,411,021**
Long Term Assets	**2,632,429**	**2,660,245**
Deferred Income Tax and Social Contribution	2,250,427	2,452,727
Recoverable Taxes	88,266	85,670
Other Assets	293,736	121,848
Fixed Assets and Investments	**16,477,212**	**16,750,776**
Investments	194,182	175,472
Biological Assets	2,801	2,994
Property, Plants and Equipments	4,223,259	4,386,563
Intangible Assets	12,056,970	12,185,747
Total Assets	**25,158,004**	**25,352,937**

Liabilities and Shareholders' Equity	12/31/2025	06/30/2026
Current Liabilities	**4,110,967**	**3,198,278**
Suppliers	575,703	548,904
Assignment of Receivables	489,543	457,318
Loans, Financing and Debentures	1,311,422	280,364
Salaries Payable	329,490	341,723
Income Tax and Social Contribution	2,325	4,924
Taxes Payable	164,639	148,308
Accounts Payable	432,385	418,860
Dividends and IOC Payable	760,917	983,890
Notes Payable	18,486	13,987
Financial Derivatives	26,057	-
Non-Current Liabilites	**8,522,663**	**7,723,530**
Loans, Financing and Debentures	8,000,041	7,182,428
Deferred Income Tax and Social Contribution	166,709	210,201
Taxes Payable	21,164	14,740
Accounts Payable	173,264	165,997
Provisions for Contingencies	153,985	144,973
Notes Payable	7,500	5,191
Shareholders' Equity	**12,524,374**	**14,431,129**
Capital	9,705,886	11,205,886
Capital Reserve	1,169,176	1,155,645
Equity Valuation Adjustments	(305,354)	(362,093)
Profit Reserves	1,964,709	1,964,709
Treasury Stock	(12,388)	(405)
Income for the Period	-	467,387
Attributed to non-controlling shareholders	2,345	-
Total Liabilities and Shareholders' Equity	**25,158,004**	**25,352,937**

Consolidated Cash Flow Statement (R$ thousand)

Table 17

	2Q25	2Q26	1H25	1H26
Cash Flows from Operating Activities				
Income (Loss) Before Income Taxes including Discontinued Operations	432,960	492,626	8,208	770,521
Depreciation and Amortization	78,744	85,920	156,262	169,864
Asset Impairment	-	-	40,098	-
Gain on Permanent Asset Disposals	(1,541)	(698)	(2,174)	(3,903)
Equity Method	(3,307)	4,488	(2,141)	7,833
Foreign Exchange (Gains) Losses	(10,862)	(2,615)	(27,548)	(18,038)
Net Interest and Related Revenue/Expenses	223,524	179,332	435,412	421,163
Expenses Related to Share Based Remuneration	(731)	(4,278)	11,234	183
Provisions and Others	27,060	(74,243)	106,617	32,563
Adjusted Results	**745,847**	**680,532**	**725,968**	**1,380,186**
Decrease (Increase) in Assets	**(322,028)**	**91,847**	**333,650**	**24,632**
Trade Accounts Receivable	(351,158)	(56,504)	647,825	(14,558)
Inventories	(21,222)	106,446	(286,130)	37,361
Recoverable Taxes	45,821	(33,783)	9,121	(65,512)
Judicial Deposits and Others	(11,470)	(8,007)	(22,478)	(12,106)
Other Accounts Receivable	16,001	83,695	(14,688)	79,447
Increase (Decrease) in Liabilities	**18,956**	**46,820**	**(46,889)**	**(64,740)**
Suppliers	60,828	24,673	13,218	(39,405)
Assignment of Receivables	(16,886)	(1,589)	(58,927)	(32,224)
Financial Derivatives	-	-	865	-
Income Tax and Social Contribution Paid	(1,599)	(10,675)	(1,983)	(14,165)
Taxes Payable	29,769	(12,832)	30,404	(22,756)
Salaries and Payroll Charges	(55,068)	48,355	(56,143)	56,741
Accounts Payable	3,604	(6,544)	38,085	(24,886)
Operations Interest Paid	(7,617)	5,945	(23,752)	13,572
Other Accounts Payable	5,925	(513)	11,344	(1,617)
Net Cash Provided by Operating Activities	**442,775**	**819,199**	**1,012,729**	**1,340,078**
Cash Flows from Investing Activities				
Capital Increase/Decrease in Subsidiaries/Affiliates	(311)	(61)	(311)	(185)
Acquisitions of Subsidiaries, Net of Cash Acquired	(13,397)	(49,523)	(13,397)	(64,323)
Acquisitions of Property, Plant and Equipment	(158,162)	(75,690)	(305,549)	(154,560)
Intangible Assets	(67,257)	(56,051)	(129,630)	(115,579)
Proceeds from the Sale of Assets with Permanent Nature	997	(115)	(10,968)	95
Interest and Others	28,909	40,773	59,173	76,858
Net Cash From Investing Activities	**(209,221)**	**(140,667)**	**(400,682)**	**(257,694)**
Cash Flows from Financing Activities				
Capital Integralization	-	-	-	1,500,000
Inflow from Loans and Financing	110,000	81,203	740,000	81,203
Treasury Stock Purchase / Sale	10,549	-	(12,539)	(8,317)
Repayment of Loans - Principal	(521,756)	(1,049,174)	(1,350,520)	(1,810,033)
Repayment of Loans - Interest	(381,580)	(415,499)	(549,218)	(735,613)
Dividends and IOC Paid	(24,646)	(27,456)	(24,646)	(147,254)
Loan Derivatives	37,380	-	49,164	(29,399)
Net Cash From Financing Activities	**(770,053)**	**(1,410,926)**	**(1,147,759)**	**(1,149,413)**
Net Increase (Decrease) in Cash and Cash Equivalents	**(536,499)**	**(732,394)**	**(535,712)**	**(67,029)**
Statement of Increase in Cash and Cash Equivalents, Net				
Cash and Cash Equivalents at the Beginning of the Period	1,740,114	2,310,906	1,739,327	1,645,541
Cash and Cash Equivalents at the End of the Period	1,203,615	1,578,512	1,203,615	1,578,512
Change in Cash and Cash Equivalent	**(536,499)**	**(732,394)**	**(535,712)**	**(67,029)**

(A free translation of the original in Portuguese)

Hypera S.A.

Quarterly Information (ITR) at June 30, 2026 and report on review of quarterly information

(A free translation of the original in Portuguese)

Report on review of quarterly information

To the Board of Directors and Shareholders
Hypera S.A.

Introduction

We have reviewed the accompanying parent company and consolidated interim accounting information of Hypera S.A. ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2026, comprising the balance sheet at that date and the statements of income and comprehensive income for the quarter and six-month periods then ended, and the statements of changes in equity and cash flows for the six-month period then ended, and explanatory notes.

Management is responsible for the preparation of the parent company and consolidated interim accounting information in accordance with the accounting standard CPC 21 - "Interim Financial Reporting", of the Brazilian Accounting Pronouncements Committee (CPC) and International Accounting Standard (IAS) 34 - "Interim Financial Reporting" issued by the International Accounting Standards Board (IASB), as well as the presentation of this information in accordance with the standards issued by the Brazilian Securities Commission (CVM), applicable to the preparation of the Quarterly Information (ITR). Our responsibility is to express a conclusion on this interim accounting information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and International Standards on Reviews of Interim Financial Information (NBC TR 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", and ISRE 2410 - "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", respectively). A review of interim information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Brazilian and International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying parent company and consolidated interim accounting information included in the quarterly information referred to above has not been prepared, in all material respects, in accordance with CPC 21 and IAS 34 applicable to the preparation of the Quarterly Information, and presented in accordance with the standards issued by the CVM.

Other matters - Statements of value added

The quarterly information referred to above includes the parent company and consolidated statements of value added for the six-month period ended June 30, 2026. These statements are the responsibility of the Company's management and are presented as supplementary information under IAS 34. These statements have been subjected to review procedures performed together with the review of the quarterly information for the purpose of concluding whether they are reconciled with the interim accounting information and accounting records, as applicable, and if their form and content are in accordance with the criteria defined in the accounting standard CPC 09 - "Statement of Value Added". Based on our review, nothing has come to our attention that causes us to believe that these statements of value added have not been properly prepared, in all material respects, in accordance with the criteria established in this accounting standard, and consistent with the parent company and consolidated interim accounting information taken as a whole.

Goiânia, August 6, 2026

PricewaterhouseCoopers
Auditores Independentes Ltda.
CRC 2GO001774/F-2

Guilherme Campos e Silva
Contador CRC 1SP218254/O-1

(A free translation of the original Portuguese)

Hypera S.A.

Quarterly Information (ITR)
at June 30, 2026

Hypera S.A.

Balance sheet

In thousands of Reais (A free translation of the original Portuguese)

Assets	Parent company June 30, 2026	Parent company December 31, 2025	Consolidated June 30, 2026	Consolidated December 31, 2025
Current assets				
Cash and cash equivalents (Note 10)	963,159	1,090,789	1,578,512	1,645,541
Accounts receivable (Note 11)	1,672,645	1,659,264	1,705,036	1,688,362
Inventory (Note 12)	720,651	839,773	1,927,036	2,079,176
Taxes recoverable (Note 13)	216,499	185,365	541,252	387,963
Derivative financial instruments (Note 4 (e))	-	26,790	2,383	26,790
Dividends receivable	-	6,229	-	6,229
Other assets (Note 14)	100,702	88,971	187,697	214,302
	3,673,656	3,897,181	5,941,916	6,048,363
Non-current assets				
Long-term receivables				
Deferred income tax and social contribution (Note 21)	2,033,766	1,773,186	2,452,727	2,250,427
Taxes recoverable (Note 13)	21,679	21,678	85,670	88,266
Other assets (Note 14)	101,702	262,235	121,848	293,736
	2,157,147	2,057,099	2,660,245	2,632,429
Biological assets	-	-	2,994	2,801
Investments (Note 15)	8,450,614	8,070,323	175,472	194,182
Property, plant and equipment (Note 16)	287,150	269,992	4,386,563	4,223,259
Intangible assets (Note 17)	10,145,883	10,152,065	12,185,747	12,056,970
	18,883,647	18,492,380	16,750,776	16,477,212
	21,040,794	20,549,479	19,411,021	19,109,641
Total assets	24,714,450	24,446,660	25,352,937	25,158,004

Liabilities and equity	Parent company June 30, 2026	Parent company December 31, 2025	Consolidated June 30, 2026	Consolidated December 31, 2025
Current liabilities				
Suppliers (Note 18)	1,059,263	1,029,194	548,904	575,703
Suppliers' assignment of receivables (Note 19)	13,717	12,934	457,318	489,543
Loans, financing and debentures (Note 20)	265,266	1,285,332	280,364	1,311,422
Salaries payable	197,019	188,542	341,723	329,490
Income tax and social contribution payable	-	-	4,924	2,325
Taxes payable (Note 22)	29,718	31,616	148,308	164,639
Notes payable	11,400	16,236	13,987	18,486
Dividends and interest on capital payable	983,890	760,917	983,890	760,917
Derivative financial instruments (Note 4 (e))	-	26,057	-	26,057
Other liabilities (Note 23)	286,007	313,200	418,860	432,385
	2,846,280	3,664,028	3,198,278	4,110,967
Non-current liabilities				
Loans, financing and debentures (Note 20)	7,182,428	8,000,041	7,182,428	8,000,041
Taxes payable (Note 22)	10,644	16,557	14,740	21,164
Deferred income tax and social contribution (Note 21)	-	-	210,201	166,709
Provision for contingencies (Note 24)	121,779	131,626	144,973	153,985
Notes payable	-	-	5,191	7,500
Other liabilities (Note 23)	122,190	112,379	165,997	173,264
	7,437,041	8,260,603	7,723,530	8,522,663
Total liabilities	10,283,321	11,924,631	10,921,808	12,633,630
Equity				
Share capital (Note 25 (a))	11,205,886	9,705,886	11,205,886	9,705,886
Capital reserves	1,155,645	1,169,176	1,155,645	1,169,176
Equity valuation adjustments	(362,093)	(305,354)	(362,093)	(305,354)
Profit reserves	1,964,709	1,964,709	1,964,709	1,964,709
Treasury shares	(405)	(12,388)	(405)	(12,388)
Income for the period	467,387	-	467,387	-
Equity attributable to the owners of the parent company	14,431,129	12,522,029	14,431,129	12,522,029
Equity attributable to non-controlling interests (Note 15(c))	-	-	-	2,345
Total equity	14,431,129	12,522,029	14,431,129	12,524,374
Total liabilities and equity	24,714,450	24,446,660	25,352,937	25,158,004

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of income
Three- and six-month periods ended June 30
In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

				Parent company
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Continuing operations				
Net revenue (Note 26)	2,402,259	4,473,132	2,189,347	3,279,598
Cost of sales (Note 27 (a))	(1,221,638)	(2,317,377)	(1,090,797)	(1,730,642)
Gross profit	**1,180,621**	**2,155,755**	**1,098,550**	**1,548,956**
Selling and marketing expenses (Note 27 (a))	(617,335)	(1,153,276)	(516,427)	(1,061,820)
General and administrative expenses (Note 27(a))	(61,561)	(124,619)	(39,916)	(93,302)
Other operating income (expenses), net (Note 27(b))	(3,978)	(37,418)	1,602	(99,400)
Equity accounting (Note 15 (b))	172,644	340,011	109,468	210,164
Income before financial income and expenses	**670,391**	**1,180,453**	**653,277**	**504,598**
Financial income (Note 27 (c))	45,338	90,514	38,538	73,987
Financial expenses (Note 27 (d))	(284,667)	(634,261)	(308,720)	(601,718)
Financial expenses, net	**(239,329)**	**(543,747)**	**(270,182)**	**(527,731)**
Income before income tax and social contribution	**431,062**	**636,706**	**383,095**	**(23,133)**
Income tax and social contribution (Note 21(c))	58,953	199,527	44,276	312,876
Net income (loss) from continuing operations	**490,015**	**836,233**	**427,371**	**289,743**
Discontinued operations				
Net income (loss) from discontinued operations	221	1,381	(682)	(3,001)
Net income for the period	**490,236**	**837,614**	**426,689**	**286,742**

The accompanying notes are an integral part of the quarterly information.

In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

				Consolidated
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Continuing operations				
Net revenue (Note 26)	2,336,699	4,354,477	2,153,937	3,234,843
Cost of sales (Note 27 (a))	(892,990)	(1,700,205)	(858,851)	(1,429,494)
Gross profit	**1,443,709**	**2,654,272**	**1,295,086**	**1,805,349**
Selling and marketing expenses (Note 27 (a))	(683,246)	(1,288,397)	(590,891)	(1,220,320)
General and administrative expenses (Note 27(a))	(97,440)	(195,564)	(72,944)	(159,100)
Other operating income (expenses), net (Note 27(b))	10,473	9,075	12,098	(7,459)
Equity accounting (Note 15 (b))	(4,488)	(7,833)	3,307	2,147
Income before financial income and expenses	**669,008**	**1,171,553**	**646,656**	**420,617**
Financial income (Note 27 (c))	63,016	127,677	49,383	99,238
Financial expenses (Note 27 (d))	(239,733)	(530,802)	(262,045)	(507,102)
Financial expenses, net	**(176,717)**	**(403,125)**	**(212,662)**	**(407,864)**
Income before income tax and social contribution	**492,291**	**768,428**	**433,994**	**12,753**
Income tax and social contribution (Note 21(c))	(2,276)	67,268	(7,898)	274,520
Net income (loss) from continuing operations	**490,015**	**835,696**	**426,096**	**287,273**
Discontinued operations				
Net income (loss) from discontinued operations	221	1,381	(682)	(3,001)
Net income for the period	**490,236**	**837,077**	**425,414**	**284,272**
Attributable to				
Owners of the parent company	490,236	837,614	426,689	286,742
Non-controlling interests (Note 15(c))	-	(537)	(1,275)	(2,470)
	490,236	**837,077**	**425,414**	**284,272**
Earnings per share				
Basic earnings per share (in R$)	0.70380	1.25192	0.67505	0.45350
Diluted earnings per share (in R$)	0.69965	1.24212	0.66928	0.45012
Earnings per share - Continuing operations				
Basic earnings per share (in R$)	0.70356	1.24985	0.67222	0.45434
Diluted earnings per share (in R$)	0.69941	1.24007	0.66647	0.45095

The accompanying notes are an integral part of the quarterly information.

In thousands of Reais, unless stated otherwise (A free translation of the original Portuguese)

				Parent company
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Net income for the period	**490,236**	**837,614**	**426,689**	**286,742**
Other comprehensive income				
Items that will be reclassified to profit or loss				
Share of other comprehensive income of joint ventures	(727)	(73,937)	(11,562)	(12,541)
Cash flow hedge - effective portion of the changes in fair value	-	(23,090)	(5,543)	(29,643)
Income tax and social contribution on other comprehensive income	-	7,850	1,874	10,068
	(727)	(89,177)	(15,231)	(32,116)
Items that will not be reclassified to profit or loss				
Cash flow hedge - effective portion of the changes in fair value	-	49,148	25,674	34,410
Income tax and social contribution on other comprehensive income	-	(16,710)	(8,729)	(11,700)
	-	32,438	16,945	22,710
Other comprehensive income, net of income tax and social contribution	(727)	(56,739)	1,714	(9,406)
Comprehensive income for the period	**489,509**	**780,875**	**428,403**	**277,336**

				Consolidated
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Net income for the period	**490,236**	**837,077**	**425,414**	**284,272**
Other comprehensive income				
Items that will be reclassified to profit or loss				
Share of other comprehensive income of joint ventures	(727)	(73,937)	(11,562)	(12,541)
Cash flow hedge - effective portion of the changes in fair value	-	(23,090)	(5,543)	(29,643)
Income tax and social contribution on other comprehensive income	-	7,850	1,874	10,068
	(727)	(89,177)	(15,231)	(32,116)
Items that will not be reclassified to profit or loss				
Cash flow hedge - effective portion of the changes in fair value	-	49,148	25,674	34,410
Income tax and social contribution on other comprehensive income	-	(16,710)	(8,729)	(11,700)
	-	32,438	16,945	22,710
Other comprehensive income, net of income tax and social contribution	(727)	(56,739)	1,714	(9,406)
Comprehensive income for the period	**489,509**	**780,338**	**427,128**	**274,866**
Attributable to				
Owners of the parent company	489,509	780,875	428,403	277,336
Non-controlling interests	-	(537)	(1,275)	(2,470)
	489,509	**780,338**	**427,128**	**274,866**

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of changes in equity
Six-month periods ended June 30
In thousands of Reais (A free translation of the original Portuguese)

		Capital reserves					Profit reserves						
	Capital	Premium on share issuance	Stock options	Debenture subscription bonus options	Treasury shares	Equity valuation adjustments	Legal reserve	Government grant reserve	Profit retention reserve	Retained earnings	Equity attributable to the owners of the parent company	Equity attributable to non-controlling interests	Total equity
At January 1, 2025	**9,705,886**	**938,150**	**194,870**	**50,244**	**(22,828)**	**(279,524)**	**330,040**	**509,024**	**670,419**	**-**	**12,096,281**	**5,538**	**12,101,819**
									-				
Stock options	-	-	8,065	-	-	-	-	-	-	-	8,065	-	8,065
Results on sales of treasury shares	-	(29,904)	-	-	-	-	-	-	-	-	(29,904)	-	(29,904)
Acquisitions of treasury shares (Note 25 (b))	-	-	-	-	(30,466)	-	-	-	-	-	(30,466)	-	(30,466)
Sales of treasury shares (Note 25 (b))	-	-	-	-	40,505	-	-	-	-	-	40,505	-	40,505
Net income for the period	-	-	-	-	-	-	-	-	-	286,742	286,742	-	286,742
Interest on capital	-	-	-	-	-	-	-	-	(83,127)	(286,742)	(369,869)	-	(369,869)
Interest attributable to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(3,101)	(3,101)
Other comprehensive income			-			-					-		-
Gains or losses on derivatives, net of tax	-	-	-	-	-	3,135	-	-	-	-	3,135	-	3,135
Share of other comprehensive income of joint ventures	-	-	-	-	-	(12,541)	-	-	-	-	(12,541)	-	(12,541)
At June 30, 2025	**9,705,886**	**908,246**	**202,935**	**50,244**	**(12,789)**	**(288,930)**	**330,040**	**509,024**	**587,292**	**-**	**11,991,948**	**2,437**	**11,994,385**
At January 1, 2025	**9,705,886**	**907,845**	**211,087**	**50,244**	**(12,388)**	**(305,354)**	**389,808**	**509,024**	**1,065,877**	**-**	**12,522,029**	**2,345**	**12,524,374**
Capital contribution	1,500,000	-	-	-	-	-	-	-	-	-	1,500,000	-	1,500,000
Stock options	-	-	6,769	-	-	-	-	-	-	-	6,769	-	6,769
Results on sales of treasury shares	-	(20,300)	-	-	-	-	-	-	-	-	(20,300)	-	(20,300)
Acquisitions of treasury shares (Note 25 (b))	-	-	-	-	(8,317)	-	-	-	-	-	(8,317)	-	(8,317)
Sales of treasury shares (Note 25 (b))	-	-	-	-	20,300	-	-	-	-	-	20,300	-	20,300
Net income for the period	-	-	-	-	-	-	-	-	-	837,614	837,614	-	837,614
Interest on capital	-	-	-	-	-	-	-	-	-	(370,227)	(370,227)	-	(370,227)
Interest attributable to non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	(2,345)	(2,345)
Other comprehensive income													
Gains or losses on derivatives, net of tax	-	-	-	-	-	17,198	-	-	-	-	17,198	-	17,198
Share of other comprehensive income of joint ventures	-	-	-	-	-	(73,937)	-	-	-	-	(73,937)	-	(73,937)
At June 30, 2026	**11,205,886**	**887,545**	**217,856**	**50,244**	**(405)**	**(362,093)**	**389,808**	**509,024**	**1,065,877**	**467,387**	**14,431,129**	**-**	**14,431,129**

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of cash flows
Six-month periods ended June 30
In thousands of Reais (A free translation of the original Portuguese)

	Parent company		Consolidated	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Cash flows from operating activities				
Income before income tax and social contribution, including discontinued operations	638,716	(27,593)	770,521	8,208
Adjustments				
Depreciation and amortization	61,321	51,343	169,864	156,262
Impairment of assets	-	-	-	40,098
Results on sales of fixed assets	(3,327)	(1,345)	(3,903)	(2,174)
Equity accounting	(340,170)	(209,995)	7,833	(2,141)
Foreign exchange losses (gains)	726	(2,020)	(18,038)	(27,548)
Interest and related expenses (income), net	543,021	529,751	421,163	435,412
Share-based compensation expenses	198	9,334	183	11,234
Provisions (reversals) and other	60,411	163,388	32,563	106,617
Adjusted income	960,896	512,863	1,380,186	725,968
Changes in assets and liabilities				
Accounts receivable	(10,746)	652,863	(14,558)	647,825
Inventory	70,173	(203,482)	37,361	(286,130)
Taxes recoverable	(10,767)	24,012	(65,512)	9,121
Deposits with courts and others	(12,144)	(22,687)	(12,106)	(22,478)
Other accounts receivable	83,048	22,181	79,447	(14,688)
Suppliers	30,140	32,411	(39,405)	13,218
Suppliers' assignments of receivables	783	(7,082)	(32,224)	(58,927)
Derivative financial instruments	-	-	-	865
Accounts payable	(1,063)	7,682	(24,886)	38,085
Taxes payable	(7,811)	(2,944)	(22,756)	30,404
Payroll and related taxes	27,826	(47,103)	56,741	(56,143)
Other accounts payable	(1,348)	12,090	(1,617)	11,344
Interest on transactions	611	(5,083)	13,572	(23,752)
Income tax and social contribution paid	-	-	(14,165)	(1,983)
Net cash provided by operating activities	1,129,598	975,721	1,340,078	1,012,729
Cash flows from investing activities				
Acquisitions of subsidiaries (less net cash upon acquisition)	(62,073)	(13,397)	(64,323)	(13,397)
Capital increases in subsidiaries/associates	(48,165)	(203,331)	(185)	(311)
Purchases of property, plant and equipment	(5,000)	(7,363)	(154,560)	(305,549)
Purchases/development of intangible assets	(11,939)	(25,663)	(115,579)	(129,630)
Proceeds from sale of fixed assets	(659)	(11,331)	95	(10,968)
Interest and other	50,646	42,452	76,858	59,173
Loans receivable	(30,184)	1,030	-	-
Net cash (used in) investing activities	(107,374)	(217,603)	(257,694)	(400,682)
Cash flows from financing activities				
Purchases of treasury shares	(8,317)	(23,088)	(8,317)	(23,088)
Derivative financial instruments	(29,399)	49,164	(29,399)	49,164
Sales of treasury shares	-	10,549	-	10,549
Capital contribution	1,500,000	-	1,500,000	-
Loans taken out	81,203	730,000	81,203	740,000
Payment of loans – principal	(1,793,110)	(1,331,890)	(1,810,033)	(1,350,520)
Payment of loans – interest	(727,904)	(545,415)	(735,613)	(549,218)
Dividends and interest on capital paid	(147,254)	(24,646)	(147,254)	(24,646)
Loans payable	(25,073)	(2,459)	-	-
Net cash (used in) financing activities	(1,149,854)	(1,137,785)	(1,149,413)	(1,147,759)
Net increase (decrease) in cash and cash equivalents	(127,630)	(379,667)	(67,029)	(535,712)
Cash and cash equivalents at the beginning of the period	1,090,789	1,236,461	1,645,541	1,739,327
Cash and cash equivalents at the end of the period	963,159	856,794	1,578,512	1,203,615
Change in cash and cash equivalents	(127,630)	(379,667)	(67,029)	(535,712)
Transactions not involving cash	**1,176**	**2,461**	**26,526**	**26,243**
Acquisitions of property, plant and equipment	1,176	2,461	26,526	26,243

The accompanying notes are an integral part of the quarterly information.

Hypera S.A.

Statement of value added (*)
Six-month periods ended June 30
In thousands of Reais (A free translation of the original Portuguese)

	Parent company		Consolidated	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Gross revenue				
Sales of goods and products, including discontinued operations	4,687,024	3,446,863	4,731,970	3,520,871
Other income	79,148	14,861	172,207	183,032
Income related to construction of own assets	2,091	2,561	111,329	104,941
Allowance for doubtful accounts	2,168	(2,280)	1,649	(2,280)
	4,770,431	3,462,005	5,017,155	3,806,564
Inputs acquired from third parties				
Costs of materials, goods and services sold	(2,392,219)	(1,759,003)	(1,288,038)	(991,935)
Materials, power, third-party services and others	(776,785)	(701,657)	(1,140,672)	(1,048,968)
Impairment of assets	(94,128)	(98,150)	(110,992)	(167,133)
	(3,263,132)	(2,558,810)	(2,539,702)	(2,208,036)
Gross value added	1,507,299	903,195	2,477,453	1,598,528
Depreciation and amortization	(61,321)	(51,343)	(169,864)	(156,262)
Net value added generated by the Company	1,445,978	851,852	2,307,589	1,442,266
Transfers of value added received				
Equity accounting	340,170	209,995	(7,833)	2,141
Financial income	90,514	73,987	127,677	99,238
Deferred income tax and social contribution	198,897	314,335	85,203	285,736
	629,581	598,317	205,047	387,115
Total value added to be distributed	2,075,559	1,450,169	2,512,636	1,829,381
Distribution of value added				
Personnel and charges	484,279	448,631	878,357	830,749
Salaries and wages	394,971	348,851	679,470	622,118
Benefits	64,827	76,780	155,276	167,860
Government Severance Indemnity Fund for Employees (FGTS)	24,481	23,000	43,611	40,771
Taxes and contributions	114,552	109,504	258,079	199,685
Federal	81,204	76,450	216,517	154,180
State	32,332	32,109	39,602	43,561
Municipal	1,016	945	1,960	1,944
Interest	633,846	601,529	529,293	506,483
Rentals	5,268	3,763	9,830	8,192
Capital remuneration	837,614	286,742	837,077	284,272
Interest on capital	370,227	369,869	370,227	369,869
Retained earnings (losses)	467,387	(83,127)	467,387	(83,127)
Non-controlling interests	-	-	(537)	(2,470)
Total value added distributed	2,075,559	1,450,169	2,512,636	1,829,381

(*) The statement of value added is not an integral part of the quarterly information under International Financial Reporting Standards (IFRS).

The accompanying notes are an integral part of the quarterly information.

(A free translation of the original Portuguese)

Hypera S.A.

Quarterly Information (ITR)
at June 30, 2026

Contents

Notes to the individual and consolidated quarterly information

(In thousands of Reais, unless stated otherwise)

1 General information

Hypera S.A. is a Brazilian pharmaceutical company (referred to herein as the "Company"), and a leader in the various markets in which it operates.[1] Its mission consists of "providing access to healthcare for the Brazilian population, offering safe, high-quality products, continually investing in innovation and growing in a sustainable way, enabling people to live longer and better." It is a publicly-held company headquartered in the city of São Paulo, in the state of São Paul (SP), Brazil. It is listed in the New Market (Novo Mercado) segment, and its shares are traded on the São Paulo stock exchange (B3 S.A. - Brasil, Bolsa e Balcão - "B3"). Together with its subsidiaries, it is referred to herein as the "Company" in this quarterly information, unless otherwise explicitly stated.

The Company's main products are as follows:

a) Under the umbrella brand Mantecorp Farmasa, the Company operates in various medical specialty areas within the Primary Care segment, being present in most of the main classes of therapeutics in the country[1/2] with products such as Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador and Rinosoro;

b) Under the Mantecorp Skincare brand, the Company offers dermo-cosmetics which are recommended by dermatologists throughout Brazil, according to information from Close-Up International. The Company also operates in this segment with the Simple Organic brand, offering organic and vegan products produced without animal cruelty, and Bioage, which is focused on the professional aesthetic treatment market;

c) The Company is a leading supplier in the Brazilian market of over-the-counter drugs[3], including brands such as Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil and Neosaldina, among others. It also offers lines of nutritional products, sweeteners and vitamin supplements, under brands such as Tamarine, Biotônico Fontoura and Zero-Cal, the latter of which has been the top-of-mind brand in Brazil for 21 years[4];

d) Through the Neo Química brand, the Company is first in the similar and generic drugs market in Brazil[5]. The brand is top-of-mind for generic drugs[4], and is present at almost all Brazilian pharmaceutical points of sale[6], which is consistent with the Company's mission to provide access to health for the Brazilian population.

e) Since 2021, the Company has also been operating through the institutional channel, comprising public and private hospitals and clinics, which represent 44% of the total pharmaceutical market in Brazil.[7] In this market, it sells brands such as injectable Bac-Sulfitrin, Buscopan and Dramin, in addition to its first exclusive product for this channel,

---

[1] IQVIA data – MAT May/26.
[2] Considering CT Level 1 classification.
[3] Hypera Total Pharmaceutical Market, OTC market segments, amounts in promotional retail price.
[4] According to Datafolha - https://top-of-mind.folha.uol.com.br/2024/10/top-medicamento-generico-traz-empate-quintuplo.shtml - Accessed on April 15, 2025.
[5] Hypera Total Pharmaceutical Market, laboratory segmentation, amounts in units – MAT May/26.
[6] IQVIA Retail Insights MAT May/26
[7] Source: IQVIA PMB | NRC (Data MAT May/26 | Amounts in PPP and HPP)

Hyfol (propofol), and the Company’s first biologic drug, Hyblut, used for treating deep vein thrombosis and pulmonary embolism.

The Company's main distribution center is located in Anápolis, in the state of Goiás, and goods production is mainly carried out by the subsidiaries Brainfarma Indústria Química Farmacêutica S.A. (“Brainfarma”) and Cosmed Indústria de Cosméticos e Medicamentos S.A. (“Cosmed”), at units located in the state of Goiás.

The Company’s research and development activities for pharmaceuticals, dermo-cosmetics and nutritional products are concentrated at the Brainfarma innovation facility in Barueri (SP), which houses technologies for the development of various forms of pharmaceutical products across the six laboratories that make up the complex.

The Company also operates an extensive sales and distribution structure, with national coverage. Its products are distributed throughout Brazil, either directly to retailers, or indirectly via distributors.

2 Summary of material accounting policies

The individual and consolidated interim financial information has been prepared in accordance with CPC 21 (R1) and International Accounting Standard (IAS) 34, issued by the International Accounting Standards Board (IASB) and applicable to the preparation of Quarterly Information (ITR). It is presented in a manner consistent with the standards issued by the Brazilian Securities and Exchange Commission applicable to the preparation of ITR, and it discloses all (and only) the applicable significant information related to the quarterly statements, which is consistent with the information utilized by the Company’s management in the performance of its duties.

The presentation of the individual and consolidated statements of value added in accordance with technical pronouncement CPC 09 – Statement of Value Added is required by Brazilian corporate legislation and the accounting practices adopted in Brazil for listed companies. The International Financial Reporting Standards (IFRS) do not require the presentation of such statements, and thus the presentation of such statements is considered supplementary information under IFRS .

The material accounting policies applied to the preparation of this individual and consolidated interim financial information are consistent with those applied and disclosed in Note 2 of the Company’s audited financial statements for the year ended December 31, 2025, as well as with those applied for the six-month comparative period ended June 30, 2026, except for standards and amendments effective from January 1, 2026.

The effects of the other amendments to the financial reporting standards effective from January 1, 2026 on the Company’s individual and consolidated interim financial information were not material.

2.1 Approval of the interim financial information

This quarterly information was approved by the Company’s Board of Directors on August 6, 2026.

3 Critical accounting estimates and judgments

Accounting estimates and judgments are evaluated on an ongoing basis, and are based on experience and other factors, including expectations of future events that are considered reasonable under the circumstances. The critical accounting estimates and judgments underlying this quarterly information have not changed relative to those published in the annual audited financial statements for 2025.

4 Financial risk management

There have been no changes in the financial risk factors or in the risk management policy compared to those described in the financial statements at December 31, 2025.

In the following tables, the financial data for the current period are presented on a comparative basis (compared with the financial data at December 31, 2025).

a. Foreign exchange risk

At June 30, 2026 and December 31, 2025, the assets and liabilities denominated in foreign currencies, and the financial instruments used to mitigate the associated exchange risks, were as follows:

						Parent company
			June 30, 2026			**December 31, 2025**
	US$ '000	**EUR '000**	**R$ '000**	**US$ '000**	**EUR '000**	**R$ '000**
Liabilities						
Suppliers	81	-	417	519	31	2,976
Suppliers' assignments of receivables	-	-	-	-	-	-
Loans and financing	-	-	-	-	56,310	363,765
Derivative instruments to mitigate risks	-	-	-	-	(54,473)	(351,896)
Other liabilities	-	-	-	-	-	-
Net exposure	81	-	417	519	1,868	14,845

						Consolidated
			June 30, 2026			**December 31, 2025**
	US$ '000	**EUR '000**	**R$ '000**	**US$ '000**	**EUR '000**	**R$ '000**
Liabilities						
Suppliers	5,283	-	27,197	10,811	817	60,837
Suppliers' assignments of receivables	25,901	-	133,705	27,111	-	149,051
Loans and financing	-	-	-	-	56,310	363,765
Derivative instruments to mitigate risks	(13,901)		(67,577)	-	(54,473)	(351,896)
Other liabilities	1,172	83	7,105	844	24	5,132
Net exposure	18,455	83	100,430	38,766	2,678	226,889

b. Cash flow or fair value risk associated with interest and inflation rates

The levels of exposure to interest rate risk on transactions related to variations in the Interbank Deposit Certificate (CDI) rate, the Long-term Interest Rate (TJLP), the Reference Rate (TR) and the Amplified Consumer Price Index (IPCA) are presented in the following table:

		June 30, 2026
	Parent company	**Consolidated**
Loans, financing and swaps – CDI	-	15,098
Financing - TJLP	184,434	184,434
Financing - TR	567,038	567,038
Financing - TLP	60,372	60,372
Debentures – CDI	5,972,739	5,972,739
Debentures – IPCA	663,110	663,110
Notes payable – CDI	5,767	5,767
Notes payable – IPCA	-	7,778
Financial investments – CDI (Note 10)	(957,260)	(1,568,714)
Net exposure	6,496,200	5,907,622

c. Credit risk

Credit risk arises from cash and cash equivalents, derivative financial instruments, deposits with banks and financial institutions, and credit exposure to wholesale and retail customers, including outstanding accounts receivable and repurchase operations.

For banks and financial institutions, the Company has a policy of diversifying its financial investments in top-tier institutions with the ratings described in Note 9 (Credit quality of financial assets).

d. Liquidity risk

The amounts disclosed in the table below represent the undiscounted future cash flow, by maturity, which includes interest to be incurred, meaning that these amounts do not match the amounts disclosed in the balance sheet.

Parent company

					June 30, 2026
	Less than one year	**From one to two years**	**From two to five years**	**More than five years**	**Overall total**
Debentures	882,799	2,462,483	5,940,449	172,427	9,458,158
Loans and financing	131,192	165,086	375,161	354,628	1,026,067
Notes payable	11,404	-	-	-	11,404
Suppliers	1,059,263	-	-	-	1,059,263
Suppliers' assignments of receivables	13,717	-	-	-	13,717
Other liabilities	244,331	41,288	35,343	13,462	334,424
Derivative financial instruments	-	-	-	-	-
	2,342,706	2,668,857	6,350,953	540,517	11,903,033

	Less than one year	From one to two years	From two to five years	More than five years	December 31, 2025 Overall total
Debentures	1,337,375	2,249,452	7,401,637	170,252	11,158,716
Loans and financing	821,641	147,682	373,447	351,678	1,694,448
Notes payable	16,236	-	-	-	16,236
Suppliers	1,029,194	-	-	-	1,029,194
Suppliers' assignments of receivables	12,934	-	-	-	12,934
Other liabilities	263,412	38,324	24,712	16,288	342,736
Derivative financial instruments	(1,673)	-	-	-	(1,673)
	3,479,119	2,435,458	7,799,796	538,218	14,252,591

Consolidated

	Less than one year	From one to two years	From two to five years	More than five years	June 30, 2026 Overall total
Debentures	882,799	2,462,483	5,940,449	172,427	9,458,158
Loans and financing	146,755	165,086	375,161	354,628	1,041,630
Notes payable	19,182	-	-	-	19,182
Suppliers	548,904	-	-	-	548,904
Suppliers' assignments of receivables	457,318	-	-	-	457,318
Other liabilities	366,681	47,755	59,739	26,156	500,331
Derivative financial instruments	(2,383)	-	-	-	(2,383)
	2,419,256	2,675,324	6,375,349	553,211	12,023,140

	Less than one year	From one to two years	From two to five years	More than five years	December 31, 2025 Overall total
Debentures	1,337,375	2,249,452	7,401,637	170,252	11,158,716
Loans and financing	849,913	147,682	373,447	351,678	1,722,720
Notes payable	16,236	-	-	-	16,236
Suppliers	575,998	-	-	-	575,998
Suppliers' assignments of receivables	489,543	-	-	-	489,543
Other liabilities	372,049	65,433	41,785	32,742	512,009
Derivative financial instruments	(1,673)	-	-	-	(1,673)
	3,639,441	2,462,567	7,816,869	554,672	14,473,549

e. Derivatives

At June 30, 2026, transactions with derivative instruments in the amount of R$ 67,577 were recorded in the consolidated financial statements. On the same date, the results of the transactions not yet settled represented gains of R$ 2,383, also in the consolidated financial statements.

At December 31, 2025, transactions with derivative instruments in the amount of R$ 448,108 were recorded both in the consolidated and parent company financial statements. On the same date, the results of the transactions not yet settled represented gains of R$ 733, both in the consolidated and parent company financial statements.

At December 31, 2025, these transactions can be summarized as follows:

Parent company

Type	Counterparties	Notional value		Fair value receivable (payable)		Gain (loss) realized	
(In R$ thousand)		Jun/26	Dec/25	Jun/26	Dec/25	Jun/26	Dec/25
Foreign currency							
Forward contracts		-	-	-	-	-	-
Long position		-	-	-	-	-	-
Short position		-	-	-	-	-	-
Swaps		-	**351,896**	-	**26,790**	**(6,309)**	**35,166**
Long position	BNP, Citibank	-	351,896	-	26,790	(6,309)	35,166
Subtotal		-	**351,896**	-	**26,790**	**(6,309)**	**35,166**
Interest rate							
Swaps – Asset Position – Fixed		-	-	-	-	-	**31,929**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	-	-	-	-	(1,308)
Short position	BNP Paribas, Itaú, BOFA, XP Investimentos, Santander	-	-	-	-	-	33,237
Equity Swap		-	**96,212**	-	**(26,057)**	**(23,090)**	**(7,378)**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	96,212	-	(26,057)	(23,090)	(7,378)
Total		-	**448,108**	-	**733**	**(29,399)**	**59,717**

Consolidated

Type	Counterparties	Notional value		Fair value receivable (payable)		Gain (loss) realized	
(In R$ thousand)		Jun/26	Dec/25	Jun/26	Dec/25	Jun/26	Dec/25
Foreign currency							
Forward contracts		**67,577**	-	**2,383**	-	-	-
Long position	ABC Brasil, Banco do Brasil, BNP Paribas, Bradesco, BTG, CitiBank, Itaú, JP Morgan, Merril Lynch, Safra, Santander, Votorantim, XP Investimentos	67,577	-	2,383	-	-	-
Short position	ABC Brasil, Banco do Brasil, JP Morgan, Merril Lynch, Votorantim, XP Investimentos	-	-	-	-	-	-
Swaps		-	**351,896**	-	**26,790**	**(6,309)**	**35,166**
Long position	BNP, Citibank	-	351,896	-	26,790	(6,309)	35,166
Subtotal		**67,577**	**351,896**	**2,383**	**26,790**	**(6,309)**	**35,166**
Interest rate							
Swaps – Asset Position – Fixed		-	-	-	-	-	**31,929**
Long position	BNP Paribas, Itaú, Merril Lynch, Santander, XP Investimentos	-	-	-	-	-	(1,308)
Short position	BNP Paribas, Itaú, BOFA, XP Investimentos, Santander	-	-	-	-		33,237
Equity Swap		-	**96,212**	-	**(26,057)**	**(23,090)**	**(7,378)**
Long position	XP Investimentos, Itaú	-	96,212	-	(26,057)	(23,090)	(7,378)
Total		**67,577**	**448,108**	**2,383**	**733**	**(29,399)**	**59,717**

f. Methodology for calculating the fair values of derivatives

(i) Foreign currency forward contracts are valued using the interpolations of the market rates of US Dollar futures contracts for each base date published by B3 S.A. – Brasil, Bolsa, Balcão (“B3”).

(ii) Swaps are valued using the interpolation of the exchange coupon market and future interbank deposit rates for each base date, as issued by B3.

g. Sensitivity analysis

The table below presents a sensitivity analysis of the financial instruments, including derivatives that describe the risks that could result in material losses for the Company, with the most likely scenario (Scenario I, based on a fluctuation of 5.1% for the US Dollar, corresponding to three standard deviations of the fluctuation during the three months of the second quarter of the year) according to management's evaluation, considering a projection period of three months, after which the next quarterly financial information containing this analysis should be released. In addition, two additional scenarios (Scenario II and Scenario III) are presented, showing deteriorations of 25% and 50%, respectively, in the exchange rates between the Brazilian Real and the US Dollar.

Parent company

Risk	**Scenario I**		**Scenario II**		**Scenario III**	
(In R$ thousand)			**25% fluctuation**		**50% fluctuation**	
	Appreciation	**Depreciation**	**Appreciation**	**Depreciation**	**Appreciation**	**Depreciation**
US Dollar quotation	-	-	-	-	-	-
Foreign currency						
Economic hedges	-	-	-	-	-	-
Forward contracts	-	-	-	-	-	-
Swaps						
Objects of the economic hedges	-	-	-	-	-	-
Net effect	-	-	-	-	-	-

Consolidated

Risk	**Scenario I**		**Scenario II**		**Scenario III**	
(In R$ thousand)			**25% fluctuation**		**50% fluctuation**	
	Appreciation	**Depreciation**	**Appreciation**	**Depreciation**	**Appreciation**	**Depreciation**
US Dollar quotation	4.899	5.425	3.872	6.453	2.581	7.743
Foreign currency						
Economic hedges	**(6,683)**	**7,023**	**(33,439)**	**33,779**	**(67,047)**	**67,387**
Forward contracts	(6,683)	7,023	(33,439)	33,779	(67,047)	67,387
Swaps	-	-	-	-	-	-
Objects of the economic hedges	**6,683**	**(7,023)**	**33,439**	**(33,779)**	**67,047**	**(67,387)**
Loans, financing and notes payable subject to short-term exchange rate variations	6,683	(7,023)	33,439	(33,779)	67,047	(67,387)
Net effect	-	-	-	-	-	-

The scenarios for monetary variations and the floating interest rates on the Company's loans, financing and notes payable projected for the third quarter of 2026 are as follows:

Parent company

Variation scenarios	**Likely scenario***	**25% change**	**50% change**
Loans – CDI	-	-	-
Financing - TJLP	17	4,210	8,419
Debentures – CDI	(7,849)	211,286	422,571
Debentures – IPCA	(7,470)	3,050	6,101
Financing - TR	(85)	2,935	5,869
Financing - TLP	(680)	278	555
Notes payable – CDI	(8)	204	408
Notes payable – IPCA	-	-	-
Financial investments	1,258	(33,863)	(67,726)
Total loss (gain)	**(14,817)**	**188,100**	**376,197**

Consolidated

Variation scenarios	Likely scenario*	25% change	50% change
Loans – CDI	(20)	534	1,068
Financing - TJLP	17	4,210	8,419
Debentures – CDI	(7,849)	211,286	422,571
Debentures – IPCA	(7,470)	3,050	6,101
Financing - TR	(85)	2,935	5,869
Financing - TLP	(680)	278	555
Notes payable – CDI	(8)	204	408
Notes payable – IPCA	(88)	36	72
Financial investments	2,061	(55,493)	(110,987)
Total loss (gain)	**(14,122)**	**167,040**	**334,076**

***Likely scenario assumptions**
Forecast CDI of 14.00% p.a.
Forecast TJLP of 9.14 % p.a.
Forecast IPCA of 0.69 % p.q.
Forecast TR of 2.05% p.a.

5 Capital management

The Company's objectives when managing its capital are to safeguard its ability to continue to offer returns to its shareholders and benefits to other stakeholders, while maintaining an optimal capital structure to reduce the cost of capital.

To maintain or adjust its capital structure, the Company may review the dividend payment policy, return capital to shareholders, or even issue new shares or sell assets in order to, for example, reduce debt.

The Company monitors its capital based on the financial leverage ratio, which is calculated as net debt divided by total capitalization. Net debt include total loans (including short- and long-term loans, financing, debentures, and notes payable, as presented in the consolidated balance sheet), less cash and cash equivalents. The total capitalization is calculated based on the sum of equity, as shown in the consolidated balance sheet, plus net debt.

The indices of financial leverage at June 30, 2026 and December 31, 2025 may be summarized as follows:

	Parent company		**Consolidated**	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Total loans, financing and debentures (Note 20)	7,447,694	9,285,373	7,462,792	9,311,463
Total notes payable	11,400	16,236	19,178	25,986
Loss (gain) on financial hedge	-	(26,790)	-	(26,790)
Less: cash and cash equivalents (Note 10)	(963,159)	(1,090,789)	(1,578,512)	(1,645,541)
Debt (cash and cash equivalents), net	6,495,935	8,184,030	5,903,458	7,665,118
Total equity	14,431,129	12,522,029	14,431,129	12,524,374
Total proceeds from financing	20,927,064	20,706,059	20,334,587	20,189,492
Net debt to adjusted equity ratio	31.0%	39.5%	29.0%	38.0%

6 Estimate of fair value

It is assumed that the balances of accounts receivable and suppliers at their book values, less losses (impairment), approximate their fair values. The fair values of financial liabilities for disclosure purposes are estimated by discounting the future contractual cash flow at the prevailing market interest rate available to the Company for similar financial instruments (Note 20 (b)).

The Company records its financial instruments in the balance sheet at their fair values, in accordance with CPC 40 (R1)/IFRS 7, which requires the disclosure of fair value measurements according to their level within the following fair value measurement hierarchy:

- Prices quoted (unadjusted) in active markets for similar assets and liabilities (Level 1).
- Inputs, other than quoted prices included in Level 1 that are available in the market for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices) (Level 2).
- Inputs for assets or liabilities that are not based on data available in the market (i.e. unobservable inputs) (Level 3).

The table below presents the Company's derivative instrument assets and liabilities at June 30, 2025, as well as their fair values.

			Parent company
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	-	-
Total assets	-	-	-
Liabilities			
Derivative financial instruments	-	-	-
Total liabilities	-	-	-

			Consolidated
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	2,383	2,383
Total assets	-	2,383	2,383
Liabilities			
Derivative financial instruments	-	-	-
Total liabilities	-	-	-

The table below presents the Company's derivative instrument assets and liabilities at December 31, 2025, as well as their fair values.

			Parent company
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	26,790	26,790
Total assets	-	26,790	26,790
Liabilities			
Derivative financial instruments	-	26,057	26,057
Total liabilities	-	26,057	26,057

			Consolidated
	Level 1	**Level 2**	**Total**
Assets			
Derivative financial instruments	-	26,790	26,790
Total assets	-	26,790	26,790
Liabilities			
Derivative financial instruments	-	26,057	26,057
Total liabilities	-	26,057	26,057

The fair values of financial instruments not traded in active markets (e.g. derivatives) are determined using valuation techniques which maximize the use of data derived from the market, where available, and which rely to the minimum extent possible on the Company's own estimates.

7 Hedge accounting

The Company holds derivative financial instruments to hedge its exposure to foreign currency variations and interest rate risk.

It is the Company's accounting policy to adopt hedge accounting, as established in CPC 48 (IFRS 9). For transactions designated as subject to hedge accounting, the Company formally documents the economic relationship between the hedging instruments and the hedged items, including the risk management objectives and the strategy for conducting the hedging transaction, as well as the methods to be used to evaluate the effectiveness of the hedging relationship.

The Company makes forward-looking and retrospective assessments, both at the time of designation of the hedging relationship, and on a continuous basis if it is expected that the hedge instruments will be "highly effective" in offsetting changes in the fair values of the respective hedged items during the period for which the hedge is designated, and if the actual results of each hedge are within the range determined by management.

Cash flow hedges

The Company has cash flow hedges for most of its transactions with suppliers and for some debentures. Gains or losses on the effective portions of these hedges are recognized in equity/other comprehensive income.

Presented below are the transactions and accounting effects arising from the adoption of this practice:

					Parent company
					June 30, 2026
Operation	Index	Hedge type	Principal amount	Asset/(liability) balance	Gain/(loss) in comprehensive income
-	-	-	-	-	-

					Consolidated
					June 30, 2026
Operation	Index	Hedge type	Principal amount	Asset/(liability) balance	Gain/(loss) in comprehensive income
NDF Purchases	USD vs. R$	Cash flow	13,091	2,383	2,383

					Parent company
					December 31, 2025
Operation	Index	Hedge type	Principal amount	Asset/(liability) balance	Gain/(loss) in comprehensive income
Swaps	HYPE3 vs CDI+	Cash flow	96,212	(26,057)	(26,057)

					Consolidated
					December 31, 2025
Operation	Index	Hedge type	Principal amount	Asset/(liability) balance	Gain/(loss) in comprehensive income
Swaps	HYPE3 vs CDI+	Cash flow	96,212	(26,057)	(26,057)

8 Financial instruments by category

Parent company

				June 30, 2026
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,672,645	-	-	1,672,645
Financial investments (Note 10)	957,260	-	-	957,260
Cash and banks (Note 10)	5,899	-	-	5,899
Derivative financial instruments	-	-	-	-
Other assets	133,293	-	-	133,293
	2,769,097	-	-	2,769,097

				June 30, 2026
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	7,447,694	-	-	7,447,694
Suppliers (Note 18)	1,059,263	-	-	1,059,263
Suppliers’ assignment of receivables (Note 19)	13,717	-	-	13,717
Other liabilities	329,672	-	-	329,672
Notes payable	11,400	-	-	11,400
Derivative financial instruments	-	-	-	-
	8,861,746	-	-	8,861,746

	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
				December 31, 2025
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,659,264	-	-	1,659,264
Financial investments (Note 10)	1,082,823	-	-	1,082,823
Cash and banks (Note 10)	7,966	-	-	7,966
Derivative financial instruments	-	26,790	-	26,790
Other assets	266,731	-	-	266,731
	3,016,784	26,790	-	3,043,574

	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
				December 31, 2025
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	9,285,373	-	-	9,285,373
Suppliers (Note 18)	1,029,194	-	-	1,029,194
Suppliers' assignment of receivables (Note 19)	12,934	-	-	12,934
Other liabilities	337,985	-	-	337,985
Notes payable	16,236	-	-	16,236
Derivative financial instruments	-	-	26,057	26,057
	10,681,722	-	26,057	10,707,779

Consolidated

	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
				June 30, 2026
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,705,036	-	-	1,705,036
Financial investments (Note 10)	1,568,714	-	-	1,568,714
Cash and banks (Note 10)	9,798	-	-	9,798
Derivative financial instruments	-	-	2,383	2,383
Other assets	119,859	-	-	119,859
	3,403,407	-	2,383	3,405,790

	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
				June 30, 2026
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	7,462,792	-	-	7,462,792
Suppliers (Note 18)	548,904	-	-	548,904
Suppliers' assignment of receivables (Note 19)	457,318	-	-	457,318
Other liabilities	495,477	-	-	495,477
Notes payable	19,178	-	-	19,178
Derivative financial instruments	-	-	-	-
	8,983,669	-	-	8,983,669

	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
				December 31, 2025
Financial assets per the balance sheet				
Accounts receivable (Note 11)	1,688,362	-	-	1,688,362
Financial investments (Note 10)	1,635,440	-	-	1,635,440
Cash and banks (Note 10)	10,101	-	-	10,101
Derivative financial instruments	-	26,790	-	26,790
Other assets	294,951	-	-	294,951
	3,628,854	26,790	-	3,655,644

				December 31, 2025
	Amortized cost	FVTPL	Designated as a cash flow hedge	Total
Financial liabilities per the balance sheet				
Loans, financing and debentures (Note 20)	9,311,463	-	-	9,311,463
Suppliers (Note 18)	575,703	-	-	575,703
Suppliers' assignment of receivables (Note 19)	489,543	-	-	489,543
Other liabilities	482,950	-	-	482,950
Notes payable	25,986	-	-	25,986
Derivative financial instruments	-	-	26,057	26,057
	10,885,645	-	26,057	10,911,702

9 Credit quality of financial assets

The credit quality of financial assets (cash and cash equivalents) can be evaluated using historical information on default rates, as follows:

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Current accounts and financial investments (*)				
AAA	963,158	1,090,789	1,578,501	1,645,540

(*) Source: Moody's, Standard & Poor's and Fitch rating agencies, on a local scale when available, otherwise on a global scale.

The residual balance of "cash and cash equivalents" in the balance sheet mainly represents cash on hand.

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Derivative financial assets				
AAA	-	26,790	2,383	26,790

No fully performing financial assets were renegotiated during the last financial year.
None of the loans with related parties are overdue or impaired.

Note 4 (c) describes the credit risks of these financial assets.

10 Cash and cash equivalents

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Cash and banks	5,899	7,966	9,798	10,101
Financial investments	957,260	1,082,823	1,568,714	1,635,440
	963,159	1,090,789	1,578,512	1,645,541

Financial investments comprise Bank Deposit Certificates (CDBs) and repurchase operations, with yields of between 97% and 101.3% of the CDI p.a. (at December 31, 2025, between 96.5% and

102% of the CDI p.a.), with a weighted average of 99.7% of the CDI p.a. (at December 31, 2025, 99.9% p.a.) and are substantially liquid.

11 Accounts receivable

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Domestic customers	1,693,625	1,683,260	1,736,580	1,722,922
Expected credit losses	(20,980)	(23,996)	(31,544)	(34,560)
	1,672,645	1,659,264	1,705,036	1,688,362

The amounts of accounts receivable that are overdue but not impaired refer to a number of independent customers with no recent history of default, and/or which are involved in negotiations in progress with a high probability of success. The aging analysis of these accounts receivable is as follows:

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Up to 3 months	19,209	6,862	19,209	6,884
From 3 to 6 months	253	155	253	155
Over 6 months	2,644	4,674	2,644	4,674
	22,106	11,691	22,106	11,713

The additions to and write-offs of the expected credit losses were recorded in profit or loss as “Selling and marketing expenses”. Amounts charged to expected credit losses are generally written off from accounts receivable when there is no expectation of recovering the funds.

The maximum exposure to credit risk at the reporting date is equivalent to the carrying amount of each class of receivable mentioned above.

Changes to the expected credit losses for the periods ended June 30, 2026 and 2025 were as follows:

	Parent company	Consolidated
Balances at December 31, 2024	(21,017)	(30,965)
(Additions)/reversals, net	(2,201)	(2,201)
Write-offs	-	-
Balances at June 30, 2025	(23,218)	(33,166)
Balances at December 31, 2025	(23,996)	(34,560)
(Additions)/reversals, net	(1,807)	(1,807)
Write-offs	4,823	4,823
Balances at June 30, 2026	(20,980)	(31,544)

12 Inventory

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Finished goods and goods for resale	763,930	897,950	864,382	935,988
Semi-finished goods	-	-	166,128	219,585
Raw materials	-	-	882,628	934,548
Maintenance and supplies	571	133	195,810	193,977
Provision for inventory losses	(43,850)	(58,310)	(181,912)	(204,922)
	720,651	839,773	1,927,036	2,079,176

The table below presents the changes in the provision for inventory losses:

	Parent company	Consolidated
Balance at 12/31/2024	(41,775)	(255,062)
Additions for the period (a)	(97,892)	(111,157)
Write-offs for the period (b)	88,197	99,432
Balance at 06/30/2025	(51,470)	(266,787)
Balance at 12/31/2025	(58,310)	(204,922)
Additions for the period (a)	(31,460)	(97,410)
Write-offs for the period (b)	45,920	120,420
Balance at 06/30/2026	(43,850)	(181,912)

(a) Refers to expected inventory losses due to the discontinuation, validity, quality and realization of inventory, in accordance with the policies established by the Company.

(b) Mainly composed of write-offs and reversals of products discarded by the Company and its subsidiaries.

13 Taxes recoverable

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
PIS/COFINS/IPI and others	46,936	39,818	147,363	135,114
ICMS	117,942	112,638	280,108	237,824
Recoverable IRPJ and CSLL	73,300	54,587	199,451	103,291
	238,178	207,043	626,922	476,229
Current	216,499	185,365	541,252	387,963
Non-current	21,679	21,678	85,670	88,266

14 Other assets

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Prepaid expenses	50,121	66,719	111,393	134,252
Bills receivable	38,539	100,914	52,226	113,966
Escrow deposits	62,550	163,797	67,633	180,985
Advances	16,819	16,109	74,027	74,750
Other	34,375	3,667	4,266	4,085
	202,404	351,206	309,545	508,038
Current	100,702	88,971	187,697	214,302
Non-current	101,702	262,235	121,848	293,736

15 Investments

The investments held by the Company are presented below:

Company	Date of incorporation	Country	Business	Interest in shares/quotas	Type of interest
Cosmed Indústria de Cosméticos e Medicamentos S.A.	12/17/2008	Brazil	Sweeteners/Pharma	100%	Direct
My Agência de Propaganda Ltda.	11/29/1999	Brazil	Advertising agency	100%	Direct
Brainfarma Indústria Química e Farmacêutica S.A.	06/24/2002	Brazil	Pharma	92.41%	Direct
Brainfarma Indústria Química e Farmacêutica S.A.	06/24/2002	Brazil	Pharma	7.59%	Indirect
Bionovis S.A.	07/15/2010	Brazil	Biotechnology	25%	Direct
Neolatina Comércio e Indústria Farmacêutica S.A.	09/15/1966	Brazil	Pharma	100%	Indirect
Simple Organic Beauty S.A.	04/29/2016	Brazil	Natural beauty dermo-cosmetics	100%	Direct
Mantecorp Participações S.A.	09/28/2016	Brazil	Holding company	100%	Direct
Bio Brands Franchising Gestão de Marcas Ltda.	08/29/2014	Brazil	Dermo-cosmetics	100%	Direct
Bio Scientific Indústria de Cosméticos Ltda.	07/13/2001	Brazil	Dermo-cosmetics	100%	Indirect
Solana Agropecuária Ltda.	11/04/1981	Brazil	Crop	100%	Indirect
Amigotech S.A.	07/02/2021	Brazil	Technology	10.8%	Direct

a. Changes in the parent company's investments

	Brainfarma	Cosmed	Mantecorp	Bionovis	My	Other		
	Cost	Cost	Cost	Cost	Cost	Cost	Goodwill	Total
Balances at January 1, 2025	5,933,047	1,417,876	325,964	130,080	11,261	187,251	64,844	8,070,323
Capital increase	-	-	-	-	-	45,452	-	45,452
Equity accounting	273,119	95,779	64	(7,833)	728	(21,846)	-	340,011
Share of discontinued equity accounting for investments	-	160	-	-	-	-	-	160
Stock options/matching/restricted	995	150	22	-	-	42	-	1,209
Equity valuation adjustments	1,511	62	-	(2,284)	-	-	-	(711)
Write-off	-	-	-	-	-	(15,007)	-	(15,007)
Dividends receivable	-	-	-	6,229	-	-	-	6,229
Other	-	-	-	-	-	2,948	-	2,948
Balances at June 30, 2026	6,208,672	1,514,027	326,050	126,192	11,989	198,840	64,844	8,450,614

	Brainfarma	Cosmed	Mantecorp	Bionovis	My	Other		
	Cost	Cost	Cost	Cost	Cost	Cost	Goodwill	Total
Balances at January 1, 2025	5,271,295	1,309,243	326,654	105,356	10,747	137,058	64,844	7,225,197
Capital increase	171,101	-	-	-	-	32,230	-	203,331
Equity accounting	182,156	33,710	6,319	2,147	149	(14,317)	-	210,164
Share of discontinued equity accounting for investments	(178)	(80)	-	-	-	89	-	(169)
Stock options/matching/restricted	1,117	109	45	-	-	(38)	-	1,233
Equity valuation adjustments	(38)	27	-	224	-	-	-	213
Dividends receivable	-	-	-	5,413	-	-	-	5,413
Other	-	-	-	-	-	631	-	631
Balances at June 30, 2025	5,625,453	1,343,009	333,018	113,140	10,896	155,653	64,844	7,646,013

The table below shows the Company's share of the profits (losses) of its main direct subsidiaries, as well as its share of their total assets and liabilities:

June 30, 2026	Assets	Liabilities	Revenue	Profit (loss)	Adjusted profit (loss) (*)
Brainfarma Indústria Química e Farmacêutica S.A.	7,546,413	1,216,390	1,917,990	211,186	295,558
Cosmed Indústria de Cosméticos e Medicamentos S.A.	1,724,456	226,877	399,616	93,558	95,779
My Agência de Propaganda Ltda.	13,596	1,692	1,920	665	728
Simple Organic Beauty S.A.	81,779	55,818	20,474	(12,279)	(16,415)
Mantecorp Participações S.A.	337,492	-	-	320	320
Bio Brands Franchising Gestão de Marcas Ltda.	129,535	11,059	20,337	(8,782)	(10,104)

December 31, 2025	Assets	Liabilities	Revenue	Profit (loss)	Adjusted profit (loss) (*)
Brainfarma Indústria Química e Farmacêutica S.A.	7,384,915	1,268,774	3,638,324	442,578	499,627
Cosmed Indústria de Cosméticos e Medicamentos S.A.	1,623,195	219,386	769,378	106,381	108,891
My Agência de Propaganda Ltda.	12,158	918	3,840	507	514
Simple Organic Beauty S.A.	81,785	73,546	70,432	(16,952)	(16,376)
Mantecorp Participações S.A.	337,148	-	-	6,016	5,148
Bio Brands Franchising Gestão de Marcas Ltda.	122,234	11,601	49,422	(13,616)	(16,143)

(*) This refers to the net income (loss) for the period adjusted for transactions between the investor and its investees.

b. Equity accounting by the parent company

	Number of shares and quotas	Adjusted equity at June 30, 2026	Ownership %	Equity accounting at June 30, 2026	Balance of the investment at June 30, 2026	Equity accounting at June 30, 2025	Balance of the investment at December 31, 2025
Cosmed Indústria de Cosméticos e Medicamen tos S.A.	2,662,160,315	1,514,027	100%	95,779	1,514,027	33,710	1,417,876
My Agência de Propaganda Ltda.	22,467,862	11,989	100%	728	11,989	149	11,261
Brainfarma Indústria Química e Farmacêutica S.A.	1,553,100,031	6,718,760	92.41%	273,119	6,208,672	182,156	5,933,047
Simple Organic Beauty S.A	789,608	45,750	100%	(11,742)	45,750	(4,762)	25,684
Bio Brands Franchising Gestão de Marcas Ltda.	141,715,454	179,769	100%	(10,104)	179,769	(9,555)	173,239
Mantecorp Participações S.A.	275,300,100	326,050	100%	64	326,050	6,319	325,964
Bionovis S.A. (*)	29,538,712	504,770	25%	(7,833)	126,192	2,147	130,080
				340,011	8,412,449	210,164	8,017,151

(*) in the consolidated refers to the Equity Accounting of Bionovis.

c. Non-controlling interests

	Equity		Profit or loss	
	June 30, 2026	December 31, 2025	June 30, 2026	June 30, 2025
Simple Organic Beauty S.A.	-	2,345	(537)	(2,470)

16 Property, plant and equipment

Parent company

Own assets	Balamced at January 1, 2025	Additions	Write-off	Depreciation	Transfer	Balances at June 30, 2026
Land	4,990	-	-	-	-	4,990
Buildings and improvements	33,947	-	-	(5,129)	1,151	29,969
Machinery, equipment and facilities	68,364	1,900	(6)	(2,605)	15	67,668
Vehicles	93	-	-	-	(93)	-
Furniture and fixtures	27,159	210	(1)	(877)	-	26,491
Other	2,519	-	-	(353)	18	2,184
Total in operation	137,072	2,110	(7)	(8,964)	1,091	131,302
Construction in progress	14,352	3,080	-	-	(1,091)	16,341
Property, plant and equipment	151,424	5,190	(7)	(8,964)	-	147,643

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2026
Buildings and improvements	47,286	1,706	(81)	(5,442)	-	43,469
Machinery, equipment and facilities	17,243	3,219	(76)	(8,910)	-	11,476
Vehicles	54,039	58,480	(11,470)	(16,487)	-	84,562
Leases	118,568	63,405	(11,627)	(30,839)	-	139,507
Total property, plant and equipment	269,992	68,595	(11,634)	(39,803)	-	287,150

Own assets	Balances at January 1, 2025	Additions	Write-off	Depreciation	Transfer	Balances at June 30, 2025
Land	4,990	-	-	-	-	4,990
Buildings and improvements	17,885	31	-	(1,911)	893	16,898
Machinery, equipment and facilities	70,585	457	(31)	(2,738)	142	68,415
Vehicles	93	-	-	-	-	93
Furniture and fixtures	26,350	1,468	-	(698)	30	27,150
Other	2,216	438	-	(294)	-	2,360
Total in operation	122,119	2,394	(31)	(5,641)	1,065	119,906
Construction in progress	29,616	4,481	(9)	-	(1,080)	33,008
Property, plant and equipment	151,735	6,875	(40)	(5,641)	(15)	152,914

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2025
Buildings and improvements	46,797	3,189	-	(5,059)	-	44,927
Machinery, equipment and facilities	20,841	473	(167)	(6,234)	-	14,913
Vehicles	71,599	35,043	(5,641)	(23,723)	-	77,278
Leases	139,237	38,705	(5,808)	(35,016)	-	137,118
Total property, plant and equipment	290,972	45,580	(5,848)	(40,657)	(15)	290,032

Consolidated

Own assets	Balances at January 1, 2025	Additions (*)	Write-off	Depreciation	Transfer	Balances at June 30, 2026
Land	290,969	-	-	-	-	290,969
Buildings and improvements	550,551	350	-	(15,847)	1,252	536,306
Machinery, equipment and facilities	2,346,514	55,170	(370)	(50,732)	73,156	2,423,738
Vehicles	1,690	-	-	(170)	(91)	1,429
Furniture and fixtures	57,930	1,819	(8)	(1,817)	83	58,007
Other	88,663	11,643	-	(13,217)	498	87,587
Total in operation	3,336,317	68,982	(378)	(81,783)	74,898	3,398,036
Construction in progress	722,196	147,108	-	-	(75,598)	793,706
Property, plant and equipment	4,058,513	216,090	(378)	(81,783)	(700)	4,191,742

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2026
Buildings and improvements	90,670	10,093	-	(8,186)	-	92,577
Machinery, equipment and facilities	18,807	3,576	(163)	(10,303)	-	11,917
Vehicles	55,269	64,782	(12,030)	(17,694)	-	90,327
Leases	164,746	78,451	(12,193)	(36,183)	-	194,821
Total property, plant and equipment	4,223,259	294,541	(12,571)	(117,966)	(700)	4,386,563

Own assets	Balances at January 1, 2025	Additions	Write-off	Depreciation	Transfer	Balances at June 30, 2025
Land	290,969	-	-	-	-	290,969
Buildings and improvements	533,732	1,012	-	(12,092)	15,622	538,274
Machinery, equipment and facilities	2,042,764	148,593	(235)	(45,961)	99,885	2,245,046
Vehicles	1,900	-	-	(81)	-	1,819
Furniture and fixtures	52,900	3,103	(2)	(1,599)	637	55,039
Other	80,882	15,518	-	(13,448)	1,692	84,644
Total in operation	3,003,147	168,226	(237)	(73,181)	117,836	3,215,791
Construction in progress	693,233	132,111	(169)	(1,167)	(117,756)	706,252
Property, plant and equipment	3,696,380	300,337	(406)	(74,348)	80	3,922,043

Right-of-use assets - leases	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2025
Buildings and improvements	93,602	12,272	-	(9,063)	-	96,811
Machinery, equipment and facilities	23,789	530	(188)	(7,213)	-	16,918
Vehicles	77,385	35,231	(7,387)	(25,408)	-	79,821
Leases	194,776	48,033	(7,575)	(41,684)	-	193,550
Total property, plant and equipment	3,891,156	348,370	(7,981)	(116,032)	80	4,115,593

(*) Investments were made mainly in the new Innovation Center, the new Pilot Plant, the new Oncology and Biologic medication factories, and the scopolamine extraction site,

17 Intangible assets

a) Balance composition

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Goodwill in non-merged companies				
Simple Organic Beauty S.A.	-	-	14,035	13,912
Bio Brands Franchising Gestão de Marcas Ltda.	-	-	43,257	43,257
Neolatina Comércio e Indústria Farmacêutica S.A.	-	-	12,204	12,204
Goodwill on acquisitions of investments in merged companies				
Mantecorp Indústria Química Farmacêutica S.A.	1,798,470	1,798,470	1,798,470	1,798,470
Darwin Prestação de Serviços de Marketing Ltda.	2,945,156	2,945,156	2,945,156	2,945,156
Laboratório Neo Química Comércio e Indústria S.A.	967,154	967,154	967,154	967,154
DM Indústria Farmacêutica Ltda.	743,029	743,029	743,029	743,029
Farmasa - Laboratório Americano de Farmacoterapia S.A.	666,808	666,808	666,808	666,808
Amazon Distribuidora de Medicamentos e Produtos Cosméticos Ltda.	52,614	52,614	52,614	52,614
Luper Indústria Farmacêutica Ltda.	45,917	45,917	45,917	45,917
Barrenne Indústria Farmacêutica Ltda.	33,955	33,955	33,955	33,955
Finn Administradora de Marcas Ltda.	17,857	17,857	17,857	17,857
	7,270,960	7,270,960	7,340,456	7,340,333
Trademarks and patents	2,706,068	2,706,207	2,727,144	2,727,283
Rights of use and software	114,868	126,250	179,706	196,815
Product development	6,429	6,478	508,191	491,450
Intangible assets in progress	47,558	42,170	1,430,250	1,301,089
	10,145,883	10,152,065	12,185,747	12,056,970

Goodwill is measured as the fair value surplus of the consideration transferred in relation to the net assets acquired, and is based mainly on future profitability, supported by appraisal reports prepared by a specialized company, using the cash flow method, then discounted to its present value. The discount rates used for the calculations were determined by adopting the weighted average cost of capital (WACC).

b) Changes to the balances

Parent company

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2026
Rights of use and trademarks	2,706,207	-	-	(139)	-	2,706,068
Rights of use and software	126,250	6,584	-	(17,966)	-	114,868
Product development	6,478	-	(19)	(288)	258	6,429
Goodwill	7,270,960	-	-	-	-	7,270,960
Total in operation	10,109,895	6,584	(19)	(18,393)	258	10,098,325
Intangible assets in progress	42,170	5,646	-	-	(258)	47,558
Total	10,152,065	12,230	(19)	(18,393)	-	10,145,883

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2025
Rights of use and trademarks	2,706,484	-	-	(139)	-	2,706,345
Rights of use and software	99,169	18,163	-	(12,833)	15	104,514
Product development	5,443	-	-	(374)	309	5,378
Goodwill	7,270,960	-	-	-		7,270,960
Total in operation	10,082,056	18,163	-	(13,346)	324	10,087,197
Intangible assets in progress	26,132	9,709	-	-	(309)	35,532
Total	10,108,188	27,872	-	(13,346)	15	10,122,729

Consolidated

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2026
Rights of use and trademarks	2,727,283	-	-	(139)	-	2,727,144
Rights of use and software	196,815	9,931	-	(27,740)	700	179,706
Product development	491,450	10,522	(19)	(23,075)	29,313	508,191
Goodwill	7,340,333	123	-	-	-	7,340,456
Total in operation	10,755,881	20,576	(19)	(50,954)	30,013	10,755,497
Intangible assets in progress	1,301,089	158,474	-	-	(29,313)	1,430,250
Total	12,056,970	179,050	(19)	(50,954)	700	12,185,747

	Balances at January 1, 2025	Additions	Write-off	Amortization	Transfer	Balances at June 30, 2025
Rights of use and trademarks	2,727,560	-	-	(139)	-	2,727,421
Rights of use and software	175,011	25,008	-	(21,423)	254	178,850
Product development	358,449	3,495	(40,098)	(15,437)	141,412	447,821
Goodwill	7,340,333	-	-	-	-	7,340,333
Total in operation	10,601,353	28,503	(40,098)	(36,999)	141,666	10,694,425
Intangible assets in progress	1,189,502	158,901	-	(2,135)	(141,746)	1,204,522
Total	11,790,855	187,404	(40,098)	(39,134)	(80)	11,898,947

c) Impairment of assets

The Company tests the impairment of its intangible assets with indefinite useful lives on an annual basis, or more often when there are indications that the value may not be recoverable. These assets mainly represent the portion of goodwill relating to expected future income and trademarks arising from business combinations.

In connection with the annual impairment test of these assets, which will be realized on December 31, 2026, the Company performs stress tests to demonstrate the existence of a reasonable gap indicating the need to record an impairment loss. Considering the performance of the Company's operations up to the date of approval of this quarterly information and the gap shown in the stress testing, management concluded that there is no indication of impairment that requires additional testing.

18 Suppliers

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Domestic suppliers	18,456	9,441	521,707	514,866
Foreign suppliers	417	2,976	27,197	60,837
Related-party suppliers (Note 28(a))	1,040,390	1,016,777	-	-
	1,059,263	1,029,194	548,904	575,703

19 Suppliers' assignments of receivables

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Domestic market (drawee risk)	7,387	7,336	282,014	307,391
Foreign market (forfaiting)	-	-	133,705	149,051
Total suppliers' assignments of receivables	7,387	7,336	415,719	456,442
Total service providers' assignments of receivables	6,330	5,598	41,599	33,101
Total assignments of receivables	13,717	12,934	457,318	489,543

Some suppliers have the option to assign the Company's receivables, without right of recourse, to financial institutions. Under these transactions, a supplier may see a reduction in its financial costs due to the financial institution taking the credit risk of the buyer into consideration.

At June 30, 2026, the discount rates in assignment operations entered into between the suppliers and financial institutions in the domestic market were between 1.09% and 1.59% p.m., with a weighted average of 1.16% p.m. (at December 31, 2025, these rates were between 0.99% and 1.51% p.m. with a weighted average of 1.19% p.m.).

At June 30, 2026, the discount rates in assignment operations entered into between the suppliers and financial institutions in the foreign market were between 5.13% and 6.76% p.a. with a weighted average of 5.74% p.a. (at December 31, 2025, these rates were between 5.37% and 7.08% p.a. with a weighted average of 5.95% p.a.).

Therefore, this operation does not alter the amounts, nature or timing of the liability (including terms, prices and conditions previously agreed upon) and does not affect the Company with any financial charges adopted by the financial institution when conducting a thorough analysis of suppliers by category. No guarantees are pledged by the Company.

Moreover, the payments made by the Company represent purchases of goods and services, are directly related to the suppliers' invoices, and do not affect its cash flow. Accordingly, the Company continues to recognize operating suppliers in the statement of cash flows.

20 Loans, financing and debentures

		Parent company		Consolidated	
	Nominal rate	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Foreign currency					
Loans (i)	EUR + 4.5016% p.a.	-	363,765	-	363,765
Local currency					
Loans	CDI + 1.20% to 1.37% p.a.	-	371,457	15,098	397,547
FCO (i) and (ii)	Fixed rate of 2.50% p.a.				
Financing (ii)	Fixed rate of 6.00% p.a.				
BNDES	TR + 2.2% p.a.; TLP + 1.1% p.a.	378,352	294,421	378,352	294,421
Debentures (ii) and (iii)	CDI + 0.85% to 2.20% p.a.; IPCA + 6.2790% to 6.4451% p.a.	6,635,850	7,797,053	6,635,850	7,797,053
FINEP	TJLP from + 1.00% p.a.; TR + 3.3% p.a.	433,492	458,677	433,492	458,677
		7,447,694	9,285,373	7,462,792	9,311,463
Current		265,266	1,285,332	280,364	1,311,422
Non-current		7,182,428	8,000,041	7,182,428	8,000,041

(i) Contracts with covenants regarding debt levels and the coverage of interest payments with respect to certain financial information (EBITDA and net interest expenses), disposals, spin-offs, mergers, amalgamations or any other forms of corporate restructuring which, if they occur, require prior approval from the financial agents. If any of these events occurs without the consent of the lenders, the outstanding balances will have their maturities accelerated. At June 30, 2026, all of the applicable covenants were met. The next measurement will be carried out on December 31, 2026.

(ii) An amount of R$ 2,545,646 related to principal and interest on loans, financing and debentures was amortized during the period.

(iii) The amount of the accounting balance of debentures takes into account the amounts of their related swaps.

The breakdown of long-term loans and financing at June 30, 2026, by year of maturity, is as follows:

	Parent company	Consolidated
2027	63,539	63,539
2028	127,080	127,080
2029	122,594	122,594
2030	73,252	73,252
2031	73,252	73,252
2032	73,252	73,252
2033	73,252	73,252
2034	73,252	73,252
2035	32,223	32,223
2036	8,645	8,645
	720,341	720,341

Debentures

On April 3, 2020, 248,500 non-convertible debentures were issued as part of the ninth public issuance of debentures, in a single series, in the amount of R$ 2,485,000, with a par value of R$ 10, and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.50% p.a. On May 23, 2024, the Company made a partial early amortization in the amount of R$ 843,000. The nominal unit value of the debentures was settled on April 3, 2026.

On August 10, 2022, 750,000 non-convertible debentures were issued as part of the 13th issuance of debentures for private placement, in three series, of the unsecured type, in the total amount of R$ 750,000, which will back up the issuance of real estate receivables certificates of the first, second and third series of the 59th Issue of True Securitizadora S.A., meaning that 750,000 debentures were issued, with a nominal unit value of R$ 1.

- The first series was in the amount of R$ 200,000 and with interest at 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.75% p.a.
- The second series was in the amount of R$ 397,641, monetarily adjusted by the IPCA released by the Brazilian Institute of Geography and Statistics (IBGE), with interest at a rate of 6.2790% p.a.
- The third series was in the amount of R$ 152,359, monetarily adjusted by the IPCA and with interest at a rate of 6.4451% p.a.

The balance of the nominal unit values of the first, second and third series debentures will be amortized in a single installment, and the series will be settled on August 16, 2027, August 15, 2029 and August 15, 2032, respectively.

On December 23, 2022, 750,000 non-convertible debentures were issued as part of the 14th public issuance of debentures, in a single series, in the amount of R$ 750,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.35% p.a. The nominal unit value of the debentures was amortized on March 17, 2026.

On April 24, 2023, 800,000 non-convertible debentures were issued as part of the 15th public issuance of debentures, in a single series, in the amount of R$ 800,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 2.20% p.a. The nominal unit value of the debentures was amortized on April 28, 2026.

On October 10, 2023, 750,000 non-convertible debentures were issued as part of the 16th public issuance of debentures, in a single series, in the amount of R$ 750,000, with a par value of R$ 1 and interest at 100% of the cumulative variations of the daily average DI rate, plus a spread of 1.35% p.a. The nominal unit value of the debentures will be amortized in two installments, with final maturity on October 10, 2028.

On January 3, 2024, the Company carried out the 17th issuance of non-convertible simple debentures, of the unsecured type, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 600,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 1.30% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on December 15, 2027, and the second on December 15, 2028.

On May 23, 2024, the Company carried out the 18th issuance of non-convertible simple debentures, of the unsecured type, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,500,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.85% p.a. The nominal unit value of the debentures will be amortized in two installments: the first on May 3, 2028, and the second on May 3, 2029.

On January 29, 2025, the Company carried out the 19th issuance of non-convertible simple debentures, of the unsecured type, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 530,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.90% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on January 15, 2029, and the second on January 15, 2030.

On August 15, 2025, the Company carried out the 20th issuance of non-convertible simple debentures, of the unsecured type, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,000,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.75% p.a. The nominal unit value of the debentures will be amortized in two consecutive installments: the first on August 15, 2029, and the second on August 15, 2030.

On December 15, 2025, the Company carried out the 21st issuance of non-convertible simple debentures, of the unsecured type, in a single series, for public distribution, with automatic registration of distribution, totaling R$ 1,250,000, with a firm guarantee of placement of the total debentures issued, with interest corresponding to 100% of the cumulative variation of the daily average DI rate, plus a spread of 0.85% p.a. The nominal unit value of the debentures will be amortized in a single installment with maturity on December 16, 2030.

Debentures – Changes

									Changes	
Public Issuance of Debentures	**Series**	**At January 1, 2025**	**Total issuance amount**	**Costs to be incurred**	**Financial charges**	**Principal amortization**	**Interest paid**	**At June 30, 2026**	**Current**	**Non-current**
9th Issuance	Single	211,455	-	-	8,549	(203,866)	(16,138)	-	-	-
13th Issuance	1st, 2nd and 3rd	847,287	-	-	60,701	-	(35,576)	872,412	22,097	850,315
14th Issuance	Single	149,858	-	-	5,108	(150,000)	(4,966)	-	-	-
15th Issuance	Single	821,239	-	-	44,334	(800,000)	(65,573)	-	-	-
16th Issuance	Single	774,378	-	-	56,931	-	(58,261)	773,048	23,701	749,347
17th Issuance	Single	602,382	-	-	45,404	-	(45,266)	602,520	3,307	599,213
18th Issuance	Single	1,534,206	-	-	109,546	-	(110,500)	1,533,252	33,947	1,499,305
19th Issuance	Single	564,086	-	-	39,440	-	(41,671)	561,855	34,425	527,430
20th Issuance	Single	1,046,544	-	-	73,550	-	(75,302)	1,044,792	50,723	994,069
21st Issuance	Single	1,245,618	-	-	92,195	-	(89,842)	1,247,971	5,563	1,242,408
	Total	**7,797,053**	**-**	**-**	**535,758**	**(1,153,866)**	**(543,095)**	**6,635,850**	**173,763**	**6,462,087**

		Unrealized transaction costs		
Public Issuance of Debentures	**Series**	**Current**	**Non-current**	**Total**
13th Issuance	1st, 2nd and 3rd	2,955	5,510	8,465
16th Issuance	Single	490	653	1,143
17th Issuance	Single	525	788	1,313
18th Issuance	Single	363	695	1,058
19th Issuance	Single	994	2,570	3,564
20th Issuance	Single	1,865	5,906	7,771
21st Issuance	Single	2,176	7,617	9,793
	Total	**9,368**	**23,739**	**33,107**

Note: accounting changes do not consider the amounts of swaps

The breakdown of long-term debentures by year of maturity is as follows:

	June 30, 2026
2027	874,105
2028	1,423,932
2029	1,981,316
2030	2,063,008
2031	59,863
2032	59,863
	6,462,087

a. Guarantees for loans and financing at June 30, 2026

	Parent company	Consolidated
Letters of guarantee (*)	811,844	811,844

(*) Letters of guarantee for the loan from FINEP (Contracts 0034/19 and 2170/23) and BNDES (Contracts 23.2.0368.1 and 24.2.0265.1).

b. Carrying amounts and estimated fair values

The carrying amounts and estimated fair values of loans, financing and debentures are as follows:

		Consolidated		Fair value	
	Nominal rate	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Foreign currency					
Loans	EUR + 4.5016% p.a.	-	363,765	-	363,765
Local currency					
Loans	CDI + 1.00% to 1.37% p.a.	15,098	397,547	15,098	397,547
FCO	Fixed rate of 2.50% p.a.				
Financing	Fixed rate of 6.00% p.a.				
BNDES	TR + 2.2% p.a.; TLP + 1.1% p.a.	378,352	294,421	378,352	294,421
Debentures	CDI + 0.75% to 2.20% p.a.; IPCA + 6.2790% to 6.4451% p.a.	6,635,850	7,797,053	6,635,850	7,797,053
FINEP	TJLP from + 1.00% p.a.; TR + 3.3% p.a.	433,492	458,677	433,492	458,677
		7,462,792	9,311,463	7,462,792	9,311,463

The fair values of some current loans are equal to their carrying amounts, since the impact of marking-to-market is not material. The fair values are based on the discounted cash flow, using a market rate ranging from CDI + +0.66% p.a. to CDI + +2.95% p.a. (December 31, 2025 - CDI + 0.67% p.a. to CDI + 2.82% p.a.).

c. Reconciliation of changes in equity with cash flow from financing activities

Parent company

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,285,373**	**16,236**	**760,917**	**425,579**	**(26,790)**	**26,057**	**12,522,029**	**23,009,401**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	-	(6,309)	(23,090)	(29,399)
Capital contribution	-	-	-	-	-	-	1,500,000	1,500,000
Loans taken out	81,203	-	-	-	-	-	-	81,203
Payments of loans - principal	(1,757,365)	-	-	(35,745)	-	-	-	(1,793,110)
Payments of loans - interest	(717,456)	(4)	-	(10,444)	-	-	-	(727,904)
Purchases of shares	-	-	-	-	-	-	(8,317)	(8,317)
Loans payable	-	-	-	(25,073)	-	-	-	(25,073)
Dividends paid	-	-	(147,254)	-	-	-	-	(147,254)
Total changes in cash flow from financing activities	**(2,393,618)**	**(4)**	**(147,254)**	**(71,262)**	**-**	**(6,309)**	**1,468,593**	**(1,149,854)**
Other changes								
Write-off	-	-	-	(20,088)	-	-	-	(20,088)
Additions	-	-	-	69,064	-	-	-	69,064
Leases	-	-	-	8,758	-	-	-	8,758
Stock options/matching/restricted	-	-	-	-	-	-	6,769	6,769
Accrued interest	555,939	433	-	9,016	26,790	(19,748)	-	572,430
Loans - acquisitions of subsidiaries	-	(5,265)	-	-	-	-	-	(5,265)
Interest on capital	-	-	370,227	-	-	-	(370,227)	-
Net income for the period	-	-	-	-	-	-	837,614	837,614
Equity valuation adjustments	-	-	-	-	-	-	(33,649)	(33,649)
Other liabilities	-	-	-	(12,870)	-	-	-	(12,870)
Total other changes related to liabilities	**555,939**	**(4,832)**	**370,227**	**53,880**	**26,790**	**(19,748)**	**440,507**	**1,422,763**
At June 30, 2026	**7,447,694**	**11,400**	**983,890**	**408,197**	**-**	**-**	**14,431,129**	**23,282,310**

Consolidated

				Liabilities	Derivatives (assets/ liabilities)			
	Loans and financing	**Notes payable**	**Dividends and interest on capital payable**	**Other liabilities**	**Derivative financial instruments (assets)**	**Derivative financial instruments (liabilities)**	**Equity**	**Total**
At January 1, 2025	**9,311,463**	**25,986**	**760,917**	**605,649**	**(26,790)**	**26,057**	**12,524,374**	**23,227,656**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	-	(6,309)	(23,090)	(29,399)
Capital contribution	-	-	-	-	-	-	1,500,000	1,500,000
Loans taken out	81,203	-	-	-	-	-	-	81,203
Payments of loans - principal	(1,767,387)	-	-	(42,646)	-	-	-	(1,810,033)
Payments of loans - interest	(719,808)	(4)	-	(15,801)	-	-	-	(735,613)
Purchases of shares	-	-	-	-	-	-	(8,317)	(8,317)
Dividends paid	-	-	(147,254)	-	-	-	-	(147,254)
Total changes in cash flow from financing activities	**(2,405,992)**	**(4)**	**(147,254)**	**(58,447)**	**-**	**(6,309)**	**1,468,593**	**(1,149,413)**
Other changes								
Write-off	-	-	-	(20,790)	-	-	-	(20,790)
Additions	-	-	-	83,767	-	-	-	83,767
Leases	-	-	-	9,787	-	-	-	9,787
Stock options/matching/restricted	-	-	-	-	-	-	6,769	6,769
Accrued interest	557,321	711	-	14,429	26,790	(19,748)	-	579,503
Loans - acquisitions of subsidiaries	-	(7,515)	-	-	-	-	-	(7,515)
Interest on capital	-	-	370,227	-	-	-	(370,227)	-
Net income for the period	-	-	-	-	-	-	837,614	837,614
Equity valuation adjustments	-	-	-	-	-	-	(33,649)	(33,649)
Other liabilities	-	-	-	(49,538)	-	-	-	(49,538)
Interest attributable to non-controlling interests	-	-	-	-	-	-	(2,345)	(2,345)
Total other changes related to liabilities	**557,321**	**(6,804)**	**370,227**	**37,655**	**26,790**	**(19,748)**	**438,162**	**1,403,603**
At June 30, 2026	**7,462,792**	**19,178**	**983,890**	**584,857**	**-**	**-**	**14,431,129**	**23,481,846**

Parent company

	Liabilities				Derivatives (assets/ liabilities)			
	Loans and financing	Notes payable	Dividends and interest on capital payable	Other liabilities	Derivative financial instruments (assets)	Derivative financial instruments (liabilities)	Equity	Total
At January 1, 2025	**9,357,947**	**17,326**	**648,559**	**376,517**	**(158,123)**	**40,259**	**12,096,281**	**22,378,766**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	61,709	(12,545)	-	49,164
Loans taken out	730,000	-	-	-	-	-	-	730,000
Payments of loans - principal	(1,299,720)	-	-	(32,170)	-	-	-	(1,331,890)
Payments of loans - interest	(528,747)	-	-	(16,668)	-	-	-	(545,415)
Purchases of shares	-	-	-	-	-	-	(23,088)	(23,088)
Sales of shares	-	-	-	-	-	-	10,549	10,549
Loans payable	-	-	-	(2,459)	-	-	-	(2,459)
Dividends paid	-	-	(24,646)	-	-	-	-	(24,646)
Total changes in cash flow from financing activities	**(1,098,467)**	**-**	**(24,646)**	**(51,297)**	**61,709**	**(12,545)**	**(12,539)**	**(1,137,785)**
Other changes								
Write-off	-	-	-	(5,738)	-	-	-	(5,738)
Additions	-	-	-	11,133	-	-	-	11,133
Leases	-	-	-	31,261	-	-	-	31,261
Stock options/matching/restricted	-	-	-	-	-	-	8,065	8,065
Purchases of shares	-	-	-	-	-	-	(7,326)	(7,326)
Accrued interest	563,963	409	-	8,376	50,052	(20,105)	-	602,695
Interest on capital	-	-	369,869	-	-	-	(369,869)	-
Net income for the period	-	-	-	-	-	-	286,742	286,742
Equity valuation adjustments	-	-	-	-	-	-	(9,406)	(9,406)
Other liabilities	-	-	-	57,919	-	-	-	57,919
Total other changes related to liabilities	**563,963**	**409**	**369,869**	**102,951**	**50,052**	**(20,105)**	**(91,794)**	**975,345**
At June 30, 2025	**8,823,443**	**17,735**	**993,782**	**428,171**	**(46,362)**	**7,609**	**11,991,948**	**22,216,326**

Consolidated

	Liabilities				Derivatives (assets/ liabilities)			
	Loans and financing	Notes payable	Dividends and interest on capital payable	Other liabilities	Derivative financial instruments (assets)	Derivative financial instruments (liabilities)	Equity	Total
At January 1, 2025	**9,380,041**	**17,326**	**648,559**	**593,758**	**(159,450)**	**40,259**	**12,101,819**	**22,622,312**
Changes in cash flow from financing activities								
Derivative financial instruments	-	-	-	-	61,709	(12,545)	-	49,164
Loans taken out	740,000	-	-	-	-	-	-	740,000
Payments of loans - principal	(1,311,350)	-	-	(39,170)	-	-	-	(1,350,520)
Payments of loans - interest	(529,929)	-	-	(19,289)	-	-	-	(549,218)
Purchases of shares	-	-	-	-	-	-	(23,088)	(23,088)
Sales of shares	-	-	-	-	-	-	10,549	10,549
Dividends paid	-	-	(24,646)	-	-	-	-	(24,646)
Total changes in cash flow from financing activities	**(1,101,279)**	**-**	**(24,646)**	**(58,459)**	**61,709**	**(12,545)**	**(12,539)**	**(1,147,759)**
Other changes								
Write-off	-	-	-	(8,056)	-	-	-	(8,056)
Additions	-	-	-	11,360	-	-	-	11,360
Leases	-	-	-	40,343	-	-	-	40,343
Stock options/matching/restricted	-	-	-	-	-	-	8,065	8,065
Purchases of shares	-	-	-	-	-	-	(7,326)	(7,326)
Accrued interest	565,160	409	-	11,856	50,052	(20,105)	-	607,372
Interest on capital	-	-	369,869	-	-	-	(369,869)	-
Net income for the period	-	-	-	-	-	-	286,742	286,742
Supplier hedges - interest paid	-	-	-	-	1,327	-	-	1,327
Equity valuation adjustments	-	-	-	-	-	-	(9,406)	(9,406)
Other liabilities	-	-	-	72,853	-	-	-	72,853
Interest attributable to non-controlling interests	-	-	-	-	-	-	(3,101)	(3,101)
Total other changes related to liabilities	**565,160**	**409**	**369,869**	**128,356**	**51,379**	**(20,105)**	**(94,895)**	**1,000,173**
At June 30, 2025	**8,843,922**	**17,735**	**993,782**	**663,655**	**(46,362)**	**7,609**	**11,994,385**	**22,474,726**

21 Deferred income tax and social contribution

a. Breakdown of deferred tax assets

Deferred tax assets include tax losses carried forward, negative bases of social contribution, and temporary differences. These assets are recognized in proportion to the likelihood of realization of the related tax benefit against the future taxable income. This is based on a study of future realization, using projections of the generation of taxable income from 2027 onward. Tax losses carried forward and negative bases of social contribution are mainly the result of the tax deductibility of goodwill arising from acquisitions of companies (Note 17), the distribution of interest on capital and the constitution of grants for investments.

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Deferred tax assets:				
Tax losses carried forward and negative CSLL bases	4,958,248	4,600,191	5,666,890	5,325,410
Contingencies	105,712	66,501	121,127	77,273
Expected credit losses	24,396	27,604	27,564	30,773
Other temporary differences	115,811	131,219	173,949	251,936
Total deferred tax assets	5,204,167	4,825,515	5,989,530	5,685,392
(-) Portion of deferred tax assets recoverable through deferred liabilities of the same company to the same tax authority (also recoverable against the calculation of current tax)	(3,170,401)	(3,052,329)	(3,536,803)	(3,434,965)
Remaining balance of deferred tax assets	2,033,766	1,773,186	2,452,727	2,250,427

b. Deferred tax liabilities

This balance mainly consists of deferred income tax and social contribution tax liabilities, arising from temporary differences between the tax basis of goodwill and its book value in the balance sheet, as the goodwill continues to be amortized for tax purposes, but ceased to be amortized in the accounting records from January 1, 2009. This temporary difference may result in amounts being added to the calculation of the taxable income for future years, when the book value of the asset is reduced (due to impairment) or settled, thus making it necessary to record a deferred tax liability.

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Goodwill	3,114,743	3,006,602	3,114,743	3,006,602
Fair value of property, plant and equipment - business combinations	-	-	64,993	64,847
Other	55,658	45,727	567,268	530,225
Total tax debt	3,170,401	3,052,329	3,747,004	3,601,674
(-) Portion of deferred tax liabilities recoverable through deferred assets of the same company to the same tax authority (also recoverable against the calculation of current tax)	(3,170,401)	(3,052,329)	(3,536,803)	(3,434,965)
Remaining balance of deferred liabilities	-	-	210,201	166,709

c. Reconciliation of income tax and social contribution expenses – continuing and discontinued operations

	Parent company		Consolidated	
	June 30, 2026	**June 30, 2025**	**June 30, 2026**	**June 30, 2025**
Profit before income tax and social contribution	638,716	(27,593)	770,521	8,208
Combined rate – %	34%	34%	34%	34%
Income tax and social contribution expenses at the combined rate	(217,164)	9,382	(261,905)	(2,695)
Equity accounting	116,167	72,449	697	589
Government grants	162,092	123,757	163,647	177,213
Interest on capital declared	125,877	125,755	125,877	125,755
Other permanent additions/exclusions	11,925	(17,008)	38,241	(24,799)
Income tax and social contribution income (expenses)	198,897	314,335	66,557	276,063
Current	-	-	(18,646)	(9,674)
Deferred	198,897	314,335	85,203	285,737
Discontinued operations	(630)	1,459	(711)	1,543
Continuing operations	199,527	312,876	67,268	274,520
	198,897	314,335	66,557	276,063
	31%	-1,139%	9%	3,363%

22 Taxes payable

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
ICMS (value added tax) payable	7,745	11,280	67,414	81,176
IPI/PIS/COFINS payable	5,192	5,602	62,296	66,941
Other taxes payable	27,425	31,291	33,338	37,686
	40,362	48,173	163,048	185,803
Current	29,718	31,616	148,308	164,639
Non-current	10,644	16,557	14,740	21,164

23 Other liabilities

	Parent company		Consolidated	
	June 30, 2026	**December 31, 2025**	**June 30, 2026**	**December 31, 2025**
Freight payable	32,733	35,620	39,157	42,320
Services provided	51,027	54,413	94,881	96,971
Commercial agreements and advertising	72,057	72,086	73,368	72,740
Revenue to elapse	41,895	40,576	43,001	42,455
Purchases of fixed assets	1,176	2,287	29,481	21,519
Lease liabilities (i)	152,272	131,711	207,603	178,857
Accrued taxes on inventory losses	1,859	2,529	16,190	17,483
Other	55,178	86,357	81,176	133,304
	408,197	425,579	584,857	605,649
Current	286,007	313,200	418,860	432,385
Non-current	122,190	112,379	165,997	173,264

(i) Lease liabilities

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Current	66,930	57,138	78,807	67,956
Non-current	85,342	74,573	128,796	110,901
	152,272	131,711	207,603	178,857

Lease liabilities refer mainly to vehicles and real estate. The changes in lease liabilities are presented in the table below:

	Parent company	Consolidated
At January 1, 2025	131,711	178,857
Payments of leases – principal	(35,745)	(42,646)
Payments of leases – interest	(10,444)	(15,801)
Write-off	(20,088)	(20,790)
Additions	69,064	83,767
Remeasurement	8,758	9,787
Accrued interest	9,016	14,429
At June 30, 2026	152,272	207,603

	Parent company	Consolidated
At January 1, 2025	151,594	207,665
Payments of leases – principal	(32,170)	(39,170)
Payments of leases – interest	(16,668)	(19,289)
Write-off	(5,738)	(8,056)
Additions	11,133	11,360
Remeasurement	31,261	40,343
Accrued interest	8,376	11,856
At June 30, 2025	147,788	204,709

a. *Maturity of installments*

Leases at June 30, 2026 can be broken down by year of maturity as follows:

	Parent company	Consolidated
Up to 2 years	36,537	42,901
2 to 5 years	35,343	59,739
More than 5 years	13,462	26,156
	85,342	128,796

b. *Tax rights on leases*

The table below shows the potential rights to PIS/COFINS recoverable embedded in the lease payments, based on the periods set out for payment:

	Parent company		Consolidated	
	Nominal	Adjusted to present value	Nominal	Adjusted to present value
Lease liability	169,121	152,272	247,942	207,603
Estimated PIS/COFINS	(5,325)	(3,815)	(10,134)	(7,469)
	163,796	148,457	237,808	200,134

c. *Agreements by term and discount rate*

The Company estimated the discount rates based on the risk-free interest rates available in the Brazilian market for agreements with similar terms. The table below shows the rates used, taking into consideration the terms of the respective leases:

	Parent company	Consolidated
Terms	Rate % p.a.	Rate % p.a.
Up to 2 years	13.35%	13.35%
From 2 to 5 years	13.70%	13.62%
More than 5 years	11.37%	11.21%

The table below shows the comparative balances of lease liabilities, rights of use, financial expenses and depreciation, considering the effects of the future inflation rates projected in the flows of the lease agreements, discounted at their nominal rates.

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Lease liabilities				
Carrying amount - IFRS/CPC 06 (R2)	152,272	131,711	207,603	178,861
Flow with projected inflation	161,058	139,574	219,582	189,539
Variation	5.77%	5.97%	5.77%	5.97%
Net right of use – closing balance				
Carrying amount - IFRS/CPC 06 (R2)	139,507	118,568	194,821	164,746
Flow with projected inflation	147,557	125,647	206,062	174,581
Variation	5.77%	5.97%	5.77%	5.97%

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
Financial expenses				
Carrying amount - IFRS/CPC 06 (R2)	(8,865)	(19,034)	(11,949)	(25,469)
Flow with projected inflation	(9,377)	(20,170)	(12,638)	(26,989)
Variation	5.77%	5.97%	5.77%	5.97%
Depreciation expenses				
Carrying amount - IFRS/CPC 06 (R2)	(30,839)	(60,877)	(36,183)	(71,231)
Flow with projected inflation	(32,618)	(64,511)	(38,271)	(75,483)
Variation	5.77%	5.97%	5.77%	5.97%

24 Provision for contingencies

At June 30, 2026, the Company had the following provisions for contingencies, and corresponding deposits with the courts related to these contingencies:

Parent company

	June 30, 2026				December 31, 2025			
	Forecast of likely loss	Contingencies assumed in business combinations	Escrow deposits	Contingencies net of escrow deposits	Forecast of likely loss	Contingencies assumed in business combinations	Escrow deposits	Contingencies net of escrow deposits
Civil	1,071	8,021	-	9,092	983	13,299	-	14,282
Labor	67,595	2	-	67,597	67,829	-	-	67,829
Tax	219,684	11,919	(219,081)	12,522	98,938	11,854	(93,315)	17,477
Administrative/other	2,626	-	-	2,626	2,686	-	-	2,686
Liabilities of former owners	29,942	-	-	29,942	29,352	-	-	29,352
	320,918	19,942	(219,081)	121,779	199,788	25,153	(93,315)	131,626

Consolidated

	June 30, 2026				December 31, 2025			
	Forecast of likely loss	Contingencies assumed in business combinations	Escrow deposits	Contingencies net of escrow deposits	Forecast of likely loss	Contingencies assumed in business combinations	Escrow deposits	Contingencies net of escrow deposits
Civil	1,151	8,021	-	9,172	1,060	13,299	-	14,359
Labor	71,957	2	-	71,959	72,272	1	-	72,273
Tax	255,926	11,919	(254,360)	13,485	121,830	11,854	(115,279)	18,405
Administrative/other	7,281	-	-	7,281	6,956	-	-	6,956
Liabilities of former owners	43,076	-	-	43,076	41,992	-	-	41,992
	379,391	19,942	(254,360)	144,973	244,110	25,154	(115,279)	153,985

Changes in contingencies

Parent company

	December 31, 2025	Indexation accruals	Additions	Reversals	Payments	June 30, 2026
Civil	14,282	592	20	(5,802)	-	9,092
Labor	67,829	3,823	6,747	(5,140)	(5,662)	67,597
Tax	110,792	9,289	116,601	(5,079)	-	231,603
Administrative/other	2,686	174	-	(234)	-	2,626
Liabilities of former owners	29,352	647	-	(57)	-	29,942
	224,941	14,525	123,368	(16,312)	(5,662)	340,860
Escrow deposits	(93,315)	(7,397)	(118,369)	-	-	(219,081)
	131,626	7,128	4,999	(16,312)	(5,662)	121,779

Consolidated

	December 31, 2025	Indexation accruals	Additions	Reversals	Payments	June 30, 2026
Civil	14,359	593	22	(5,802)	-	9,172
Labor (a)	72,273	4,002	7,710	(5,731)	(6,295)	71,959
Tax (b)	133,684	10,260	128,980	(5,079)	-	267,845
Administrative/other	6,956	366	1,206	(1,247)	-	7,281
Liability of former owners (c)	41,992	1,351	-	(267)	-	43,076
	269,264	16,572	137,918	(18,126)	(6,295)	399,333
Escrow deposits	(115,279)	(8,273)	(130,808)	-	-	(254,360)
	153,985	8,299	7,110	(18,126)	(6,295)	144,973

(a) The additions refer to 67 new labor lawsuits, while the reversals refer to 87 labor lawsuits and the payments refer to fourteen labor lawsuits.
(b) The additions refer to two lawsuits related to SAT/RAT, previously classified as possible loss that were reassessed and started to be classified as probable loss and included in the provision for contingencies.
(b) The additions refer to lawsuits that are the responsibility of the former owners. In these cases, the Company recognizes an obligation to settle lawsuits and records an asset to be reimbursed by the former owners when the contingency is paid.

						Parent company
	December 31, 2024	Indexation accruals	Additions	Reversals	Payments	June 30, 2025
Civil	13,416	441	8	(110)	-	13,755
Labor	71,881	3,547	6,866	(2,522)	(10,745)	69,027
Tax	62,615	4,177	24,010	-	(3)	90,799
Administrative/other	2,380	182	-	-	-	2,562
Liabilities of former owners	28,872	613	42	(849)	-	28,678
	179,164	8,960	30,926	(3,481)	(10,748)	204,821
Escrow deposits	(49,184)	(3,105)	(20,886)	-	-	(73,175)
	129,980	5,855	10,040	(3,481)	(10,748)	131,646

						Consolidated
	December 31, 2024	Indexation accruals	Additions	Reversals	Payments	June 30, 2025
Civil	13,493	441	8	(110)	-	13,832
Labor (a)	75,568	3,716	7,087	(2,605)	(10,854)	72,912
Tax	84,324	5,113	24,010	(612)	(3)	112,832
Administrative/other	6,213	374	5	(319)	-	6,273
Liabilities of former owners (b)	34,014	943	1,338	(849)	-	35,446
	213,612	10,587	32,448	(4,495)	(10,857)	241,295
Escrow deposits	(70,032)	(3,828)	(21,059)	603	-	(94,316)
	143,580	6,759	11,389	(3,892)	(10,857)	146,979

Possible contingencies

The Company and its subsidiaries are involved in labor, civil, tax and regulatory lawsuits for which the current evaluation of the likelihood of success, based on the advice of legal counsel, as well as on the relevant legal characteristics of each lawsuit, do not require a provision to be recorded, either because the expectation of loss is classified as "possible", or due to an exclusion of liability as part of a contractual agreement.

	Parent company		Consolidated	
	June 30, 2026	December 31, 2025	June 30, 2026	December 31, 2025
	Possible loss	Possible loss	Possible loss	Possible loss
Civil	54,978	51,891	55,492	52,373
Labor	190,845	209,975	234,503	239,087
Tax	58,789	113,077	92,197	139,975
Administrative/other	21,111	20,363	23,823	24,212
Liabilities of former owners	28,290	27,051	260,225	237,938
	354,013	422,357	666,240	693,585

25 Share capital

a. Share capital

At June 30, 2026, the Company was authorized to increase its share capital up to the limit of R$ 11,920,694, in accordance with a provision of its bylaws and a decision by the Board of Directors at the Special General Meeting on April 23, 2024.

The share capital at June 30, 2026 was R$ 11,205,886 (at December 31, 2025 - R$ 9,705,886), represented by 704,009,059 common shares (at December 31, 2025 - 633,420,823).

On February 3, 2026, Hypera's capital was increased by R$ 1,500,000, as approved at a Board of Directors' Meeting.

b. Treasury shares

The changes in the number of treasury shares were as shown in the table below:

	Number	Amount
At 12/31/2024	723,554	22,828
Acquisitions during the period	1,282,000	30,466
Sales during the period	(1,523,143)	(40,505)
At 06/30/2025	482,411	12,789

	Number	Amount
At 12/31/2025	467,311	12,388
Acquisitions during the period	377,000	8,317
Sales during the period	(827,507)	(20,300)
At 06/30/2026	16,804	405

c. Interest on capital

On March 26, 2026, the Board of Directors approved the payment of interest on capital to the Company's shareholders, in the amount of R$ 185,049.

On June 23, 2026, the Board of Directors approved the payment of interest on capital to the Company's shareholders, in the amount of R$ 185,178.

26 Revenue

The reconciliation between the gross and net revenue is as follows:

				Parent company
	04/01/2026 to 06/30/2026	01/01/2026 to 06/30/2026	04/01/2025 to 06/30/2025	01/01/2025 to 06/30/2025
Gross revenue from products	2,908,382	5,462,488	2,661,013	4,158,720
Returns	(36,122)	(91,105)	(40,350)	(111,298)
Unconditional discounts	(126,228)	(250,778)	(120,510)	(187,642)
Net revenue from returns and unconditional discounts	2,746,032	5,120,605	2,500,153	3,859,780
Promotional discounts	(230,169)	(433,581)	(206,114)	(412,917)
Taxes	(113,604)	(213,892)	(104,692)	(167,265)
Net revenue	2,402,259	4,473,132	2,189,347	3,279,598

				Consolidated
	04/01/2026 to 06/30/2026	01/01/2026 to 06/30/2026	04/01/2025 to 06/30/2025	01/01/2025 to 06/30/2025
Gross revenue from products	2,931,763	5,509,774	2,702,842	4,239,453
Returns	(36,603)	(91,922)	(43,009)	(114,663)
Unconditional discounts	(126,839)	(252,267)	(121,478)	(190,418)
Net revenue from returns and unconditional discounts	2,768,321	5,165,585	2,538,355	3,934,372
Promotional discounts	(230,194)	(433,615)	(206,376)	(413,501)
Taxes	(201,428)	(377,493)	(178,042)	(286,028)
Net revenue	2,336,699	4,354,477	2,153,937	3,234,843

The Company does not present its revenue disaggregated by product line, since essentially: (a) the nature and the economic risk factors of the products are similar; (b) there are no significant distinctions in terms of consumers and customers; (c) the Company only operates in the Brazilian market; and (d) the presentations made to investors mentioning different types of products only reflect different go-to-market models. Therefore, the Company optimizes synergies between these different models, leveraging a single sell-out structure.

In addition, decisions on the resources to be allocated are not categorized by business segment, but rather individually for each product to be launched, resulting in assessments of the general performance and operating results being made across all of the products in the portfolio.

27 Breakdown of the statement of income accounts

a. Operating expenses and cost of sales

				Parent company
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Cost of sales	(1,221,638)	(2,317,377)	(1,090,797)	(1,730,642)
Raw materials	-	-	-	-
Packaging materials	-	-	-	-
Labor	-	-	-	-
Depreciation and amortization expenses	-	-	-	-
Resale	(1,176,141)	(2,223,249)	(1,036,621)	(1,632,493)
Losses on inventory	(45,497)	(94,128)	(54,176)	(98,149)
Changes in inventory/others	-	-	-	-
Selling and marketing expenses	(617,335)	(1,153,276)	(516,427)	(1,061,820)
Marketing expenses	(413,720)	(750,835)	(357,908)	(715,319)
Advertising and consumer promotion	(116,688)	(216,154)	(115,519)	(249,539)
Trade deals	(76,875)	(137,444)	(57,229)	(120,813)
Market surveys and others	(2,314)	(3,775)	(1,209)	(4,014)
Medical visits, promotions, gifts and samples	(217,843)	(393,462)	(183,951)	(340,953)
Selling expenses	(203,615)	(402,441)	(158,519)	(346,501)
Sales force	(99,934)	(201,387)	(81,015)	(181,526)
Freight and logistics expenses	(62,164)	(123,173)	(43,391)	(89,606)
Research and development	(4,666)	(8,772)	(2,975)	(8,269)
Depreciation and amortization expenses	(16,367)	(31,375)	(13,512)	(27,926)
Other expenses	(20,484)	(37,734)	(17,626)	(39,174)
General and administrative expenses	(61,561)	(124,619)	(39,916)	(93,302)
Payroll and related taxes	(33,351)	(69,843)	(19,383)	(54,174)
Services, lawyers, advisors and auditors	(15,324)	(28,880)	(10,401)	(18,450)
Depreciation and amortization expenses	(9,801)	(19,969)	(7,591)	(15,255)
Other expenses	(3,085)	(5,927)	(2,541)	(5,423)

				Consolidated
	04/01/2026 to 06/30/2026	01/01/2026 to 06/30/2026	04/01/2025 to 06/30/2025	01/01/2025 to 06/30/2025
Cost of sales	(892,990)	(1,700,205)	(858,851)	(1,429,494)
Raw materials	(265,141)	(516,212)	(265,642)	(518,123)
Packaging materials	(127,729)	(241,963)	(121,143)	(231,802)
Labor	(186,016)	(355,593)	(157,345)	(311,789)
Depreciation and amortization expenses	(30,478)	(60,587)	(30,286)	(59,931)
Resale	(131,235)	(312,696)	(203,543)	(371,543)
Losses on inventory	(35,127)	(110,993)	(45,947)	(127,035)
Changes in inventory/others	(117,264)	(102,161)	(34,945)	190,729
Selling and marketing expenses	(683,246)	(1,288,397)	(590,891)	(1,220,320)
Marketing expenses	(410,928)	(746,707)	(361,441)	(728,633)
Advertising and consumer promotion	(123,339)	(226,261)	(120,040)	(258,739)
Trade deals	(77,647)	(138,777)	(57,472)	(121,258)
Market surveys and others	(2,314)	(3,775)	(1,209)	(4,014)
Medical visits, promotions, gifts and samples	(207,628)	(377,894)	(182,720)	(344,622)
Selling expenses	(272,318)	(541,690)	(229,450)	(491,687)
Sales force	(108,355)	(216,198)	(87,970)	(195,903)
Freight and logistics expenses	(69,624)	(138,290)	(49,326)	(102,248)
Research and development	(33,851)	(71,454)	(39,453)	(85,742)
Depreciation and amortization expenses	(36,538)	(71,618)	(32,111)	(62,899)
Other expenses	(23,950)	(44,130)	(20,590)	(44,895)
General and administrative expenses	(97,440)	(195,564)	(72,944)	(159,100)
Payroll and related taxes	(53,507)	(111,129)	(39,254)	(94,435)
Services, lawyers, advisors and auditors	(20,868)	(39,243)	(14,735)	(26,031)
Depreciation and amortization expenses	(18,745)	(37,220)	(15,091)	(30,853)
Other expenses	(4,320)	(7,972)	(3,864)	(7,781)

b. Other operating income (expenses), net

				Parent company
	04/01/2026 to 06/30/2026	01/01/2026 to 06/30/2026	04/01/2025 to 06/30/2025	01/01/2025 to 06/30/2025
Potential gains (losses) and other	(7,869)	(37,941)	4,410	(93,907)
Depreciation and amortization expenses	(206)	(476)	(279)	(559)
Civil and labor contingencies	4,097	999	(2,529)	(4,934)
	(3,978)	(37,418)	1,602	(99,400)

				Consolidated
	04/01/2026 to 06/30/2026	01/01/2026 to 06/30/2026	04/01/2025 to 06/30/2025	01/01/2025 to 06/30/2025
Potential gains (losses) and other	7,037	9,460	16,010	352
Depreciation and amortization expenses	(192)	(402)	(1,228)	(2,525)
Civil and labor contingencies	3,628	17	(2,684)	(5,286)
	10,473	9,075	12,098	(7,459)

c. Financial income

				Parent company
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Interest income	11,444	24,802	9,954	18,622
Income from financial investments and others	33,894	65,712	28,584	55,365
	45,338	90,514	38,538	73,987

				Consolidated
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Interest income	13,083	28,044	11,533	21,762
Income from financial investments and others	49,933	99,633	37,850	77,476
	63,016	127,677	49,383	99,238

d. Financial expenses

				Parent company
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Interest on financing	(13,038)	(24,689)	(9,995)	(18,500)
Interest on borrowing	-	(37,581)	(24,492)	(58,440)
Indexation accruals on contingencies	(8,465)	(13,878)	(4,127)	(8,347)
Debentures	(245,227)	(525,336)	(261,082)	(494,763)
Interest and commission on letters of guarantee	(1,636)	(2,916)	(1,328)	(2,522)
Bank expenses, discounts granted and others	(12,401)	(20,810)	(4,173)	(12,296)
Cost of hedges and exchange variations on loans	-	(796)	666	2,026
Cost of hedges and exchange variations on suppliers	9	71	(19)	(5)
Reversals of present value adjustments	(4,671)	(8,865)	(4,782)	(9,952)
Capitalized interest	2,403	3,350	2,195	4,051
Other	(1,641)	(2,811)	(1,583)	(2,970)
	(284,667)	(634,261)	(308,720)	(601,718)

				Consolidated
	04/01/2026 to 06/30/2026	**01/01/2026 to 06/30/2026**	**04/01/2025 to 06/30/2025**	**01/01/2025 to 06/30/2025**
Interest on financing	(13,038)	(24,689)	(9,995)	(18,500)
Interest on borrowing	(771)	(39,364)	(24,962)	(59,549)
Indexation accruals on contingencies	(9,274)	(15,221)	(4,714)	(9,644)
Debentures	(245,227)	(525,336)	(261,082)	(494,763)
Interest and commission on letters of guarantee	(1,768)	(3,061)	(1,329)	(2,534)
Bank expenses, discounts granted and others	(12,701)	(21,578)	(4,308)	(12,622)
Cost of hedges and exchange variations on loans	-	(796)	666	2,026
Cost of hedges and exchange variations on suppliers	2,614	18,834	10,197	25,523
Reversals of present value adjustments	(6,437)	(11,949)	(6,438)	(13,347)
Capitalized interest	51,237	100,546	44,191	84,163
Other	(4,368)	(8,188)	(4,271)	(7,855)
	(239,733)	(530,802)	(262,045)	(507,102)

28 Related-party transactions

The Company is a publicly traded company with its shares traded on the B3, under a shareholders' agreement entered into on July 7, 2025, for which the main signatories were: Mr. João Alves de Queiroz Filho, holding 25.93% of the Company's capital, Maiorem S.A. de C.V. holding 14.74%, and Votorantim S.A. holding 16.34%. The other signatories to the shareholders' agreement hold

0.12% of the Company's share capital, and the remaining 42.51% of the shares are held by various smaller shareholders.

Transactions and balances

The main asset and liability balances, and the transactions between related parties that impacted the results for the year, arise from transactions between the Company and its subsidiaries, which management considers to have been conducted under normal market conditions and within normal timeframes for the respective types of transactions.
Loans with related parties are indexed to the CDI, plus a spread.

In commercial relationships with related parties, prices are established based on the characteristics and nature of each transaction. In this case, both Cosmed and Brainfarma manufacture and sell almost the entirety of their production to the Company, for sale to the market.

Trading transactions involving the sale and purchase of products, raw materials, and the contracting of services and rentals, as well as financial transactions involving loans and fundraising between group companies, are presented below:

- The rental agreement with Brainfarma Indústria Química Farmacêutica S.A. is indexed to the IGPM-FGV, with an undetermined maturity, which may be extended as agreed between the parties.

a. In assets and liabilities

					Parent company
					June 30, 2026
Related parties	Cash and cash equivalents	Other amounts receivable	Suppliers	Accounts payable	Other amounts payable
Cosmed Indústria de Cosméticos e Medicamentos S.A.	-	25,646	(194,692)	-	-
My Agência de Propaganda Ltda.	-	5	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	-	6,461	(845,484)	(2,761)	-
Bio Brands Franchising Gestão de Marcas Ltda.	-	92	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	-	-	(214)	-	-
Banco Votorantim S.A.	62,443	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(162)	-
Total	62,443	32,204	(1,040,390)	(2,923)	-

					Consolidated
					June 30, 2026
Related parties	Cash and cash equivalents	Other amounts receivable	Suppliers	Accounts payable	Other amounts payable
Banco Votorantim S.A.	156,371	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(295)	-
Total	156,371	-	-	(295)	-

					Parent company
					December 31, 2025
Related parties	Cash and cash equivalents	Other amounts receivable	Suppliers	Accounts payable	Other amounts payable
Cosmed Indústria de Cosméticos e Medicamentos S.A.	-	-	(153,803)	-	(25,075)
My Agência de Propaganda Ltda.	-	23	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	-	1,905	(855,445)	-	-
Megatelecom Telecomunicações S.A.	-	35	-	-	-
Bio Brands Franchising Gestão de Marcas Ltda.	-	92	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	-	-	(7,529)	-	-
Banco Votorantim S.A.	28,695	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(143)	-
Total	28,695	2,055	(1,016,777)	(143)	(25,075)

					Consolidated
					December 31, 2025
Related parties	Cash and cash equivalents	Other amounts receivable	Suppliers	Accounts payable	Other amounts payable
Megatelecom Telecomunicações S.A.	-	35	-	-	-
Banco Votorantim S.A.	111,325	-	-	-	-
Samm Tecnologia e Telecomunicações S.A.	-	-	-	(268)	
Total	111,325	35	-	(268)	-

b. In income for the period

								Parent company
								June 30, 2026
	Transactions		Other (expenses)/income					Interest
Related parties	Purchases of goods/products	Rental income	Advertising	Lease amortization	Services provided	Shared expenses	Financial expenses	Financial income
Cosmed Indústria de Cosméticos e Medicamentos S.A.	(399,616)	-	-	-	-	(6,144)	-	-
My Agência de Propaganda Ltda.	-	-	(1,920)	-	-	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	(1,916,307)	-	-	(1,335)	-	(47,096)	(30)	-
Megatelecom Telecomunicações S.A.	-	79	-	-	-	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	(22,788)	-	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	3,581
Samm Tecnologia e Telecomunicações S.A.	-	-	-	-	(728)	-	-	-
Total	(2,338,711)	79	(1,920)	(1,335)	(728)	(53,240)	(30)	3,581

								Consolidated
								June 30, 2026
			Other (expenses)/income					Interest
Related parties	Purchases of goods/products	Rental income	Advertising	Lease amortization	Services provided	Shared expenses	Financial expenses	Financial income
Megatelecom Telecomunicações S.A.	-	79	-	-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	9,266
Samm Tecnologia e Telecomunicações S.A.	-	-	-	-	(1,477)	-	-	-
Total	-	79	-	-	(1,477)	-	-	9,266

								Parent company
								June 30, 2025
	Transactions		Other (expenses)/income					Interest
Related parties	Purchases of goods/products	Rental income	Advertising	Lease amortization	Services provided	Shared expenses	Financial expenses	Financial income
Cosmed Indústria de Cosméticos e Medicamentos S.A.	(382,758)	-	-	-	-	(6,083)	-	-
My Agência de Propaganda Ltda.	-	-	(1,920)	-	-	-	-	-
Simple Organic Beauty S.A.	-	-	(434)	-	-	-	-	-
Brainfarma Ind. Quim. e Farmacêutica S.A.	(1,611,927)	-	-	(580)	-	(40,167)	(9)	-
Megatelecom Telecomunicações S.A.	-	295		-	(337)	-	-	-
Bio Scientific Indústria de Cosméticos Ltda.	(17,341)	-		-	-	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	2,560
Actual Assessoria Contábil SS	-	-	-	-	(8)	-	-	-
	(2,012,026)	**295**	**(2,354)**	(580)	**(345)**	**(46,250)**	(9)	**2,560**

								Consolidated
								June 30, 2025
	Transactions		Other (expenses)/income				Interest	
Related parties	Purchases of goods/products	Rental income	Advertising	Lease amortization	Services provided	Shared expenses	Financial expenses	Financial income
Megatelecom Telecomunicações S.A.	-	295	-	-	(628)	-	-	-
Actual Assessoria Contábil SS	-	-	-	-	(8)	-	-	-
Banco Votoratim S/A	-	-	-	-	-	-	-	7,469
	-	**295**	-	-	**(636)**	-	-	**7,469**

c. Compensation of key management personnel

Key management personnel includes all members of the Board of Directors, Supervisory Board, Audit Committee and Statutory Directors. The compensation paid or payable to key management personnel was as follows:

	Parent company		Consolidated	
	June 30, 2026	**June 30, 2025**	**June 30, 2026**	**June 30, 2025**
Salaries and other short-term benefits	9,635	6,637	9,635	6,637
Board members' fees	3,928	3,587	3,928	3,587
Share-based payments	3,423	4,868	3,423	4,868
	16,986	15,092	16,986	15,092

Note: the amounts for 2026 are an estimate.

29 Other matters

Accounting impacts related to climate change

The Company continuously monitors the potential impacts of the climate change on its operations, including physical and transition risks. Considering the location of its production units and the mitigation measures adopted, such as water reuse systems, on-site water infrastructure, and self-generation of solar energy, Management believes that its exposure to such risks is currently limited. In addition, the Company periodically tracks relevant environmental indicators, including greenhouse gas emissions, water consumption, and waste management.

Based on the evaluations carried out up to the base date of the financial statements, no material impacts resulting from climate change were identified that required adjustments to the carrying amounts of assets and liabilities, nor the recognition of provisions or specific additional disclosures. The Company continues to monitor the evolution of the climate and regulatory scenarios and their potential impacts on the accounting estimates and assumptions.

Consumption Tax Reform

On December 20, 2023, Constitutional Amendment 132 was enacted, establishing the tax reform for taxes on consumption (the "Reform"). Constitutional Amendment 132 establishes that specific aspects of the new taxes (such as the rates) will be determined by laws, such as complementary laws No. 214, of January 16, 2025, and No. 227, of January 13, 2025. The transition to the new tax system, which will occur gradually from 2027 to 2032, will result in the progressive loss of any tax benefits enjoyed by the Company.

The Reform model is based on a dual VAT divided into two jurisdictions, one federal (Contribution on Goods and Services (CBS)) and the other sub-national (Tax on Goods and Services (IBS)), which will replace the following existing taxes: PIS, COFINS, ICMS and ISS.

A Selective Tax (IS) was also created, under federal jurisdiction, which will be levied on the production, extraction, sale or import of goods and services which are harmful to health and the environment, under the terms of the complementary laws.

There will be a transition period up to 2032, during which the two tax systems – old and new – will coexist. The impact of the Reform on the calculation of the abovementioned taxes, from the beginning of the transition period, will only be fully known upon the conclusion of the regulation of the outstanding matters by the complementary laws. Consequently, the Reform did not result in any impact on the quarterly information as at June 30, 2026.